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CHAPTER I 
 
INTRODUCTION 
 
History of Autism Spectrum Disorders 
Autism spectrum disorders (ASD, OMIM 209850) are complex, neurodevelopmental 
disorders characterized by impairments in social communication and the presence of 
restricted and repetitive behavioral patterns13. Autism was first described in 1943 by Dr. 
Leo Kanner102. Dr. Kanner described 11 patients, mostly boys, having a combination of 
severe social dysfunction, variable communication deficits, and the presence of 
repetitive restrictive behaviors. Interesting observations based on these initial case 
studies included the identification of large head size in approximately half of the 
subjects. Dr. Kanner also postulated a biological, genetic basis for the disorder. 
However, it was not until much later that autism began to be considered a distinct 
disorder in psychiatric diagnostic manuals. Since then, prevalence estimates have 
steadily been increasing with current estimates in the United States as high as 1 in 88 
children1. These estimates vary widely across all sites, by sex (ASD are estimated to be 
almost 5 times more common among boys), and by racial/ethnic group.  
There are numerous possible explanations for the substantial increase in ASD 
prevalence over such a short period of time. One is that the concept of autism has 
broadened from what was previously considered a 'strict' diagnosis of autistic disorder, 
to include individuals of normal intelligence with adequate language skills (DSM-IV 
Asperger Disorder), those not quite meeting diagnostic criteria in all three domains 
(DSM-IV Pervasive Developmental Disorders-Not Otherwise Specified), and those who 
develop normally for a period of time followed by regression in skills or a series of 
regressions in skills (DSM-IV Childhood Disintegrative Disorder)12. It is notable these 
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diagnoses are not based on etiology, but on expert observation and assessment of 
behavioral and cognitive characteristics. How these clinical domains relate to underlying 
dysfunction in specific cognitive domains is essentially unknown. 
Even within more unified diagnostic definitions, the severity of clinical presentation is 
quite heterogeneous. Some affected individuals also present with various comorbidities 
(i.e. epilepsy, mental retardation), endophenotypes (i.e. presence of savant skills, 
specific language impairment), and biomarkers (i.e. macrocephaly, hyperserotonemia)62, 
76, 151, 178, 209.  Thus, autistic disorder appears to be not a single entity but rather a 
complex phenotype expressing a continuum of symptom severity and neurocognitive 
impairments. This is reflected in the recent change in diagnostic criteria for ASD 
between the DSM-IV and the DSM-5. These revisions were motivated by the lack of 
empirical data supporting separate disorders within the autism spectrum13. 
 
Genetics of Autism Spectrum Disorders 
ASD was also for a long time not considered to have any underlying genetic basis81. 
The first evidence for an inherited genetic component to autism came from twin studies 
published in 197760, 61. These initial twin studies demonstrated a genetic susceptibility to 
the disorder and provided substantial evidence supporting biological origins. To date, 
there is overwhelming evidence suggesting strong genetic susceptibility factors 
underlying ASD. The sibling recurrence risk is estimated at 45–90 times greater than the 
population risk. Current estimates from twin studies indicate 58-60% of monozygotic 
twins are concordant for the full syndrome and 50-90% are concordant for related social 
or cognitive abnormalities21, 45, 79. There are also a number of syndromes with well-
defined genetic causes associated with ASD. These include, but are not limited to, Rett 
syndrome, tuberous sclerosis, neurofibromatosis, and Fragile X Syndrome14, 48, 104, 228. 
The hallmark presentations of these syndromes are more homogeneous profiles of 
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characteristic physical features, neurological impairment, and ASD symptoms. However, 
only a very small percentage of individuals with ASD (<1%) have an identifiable genetic 
etiology known to cause these monogenic disorders3. 
The reported prevalence and heritable nature of ASD suggests that genetic variation 
present at relatively common frequencies in the overall population contribute to the 
genetic etiology underlying these disorders. Numerous studies have evaluated the 
involvement of common variation in ASD. Results from these studies implicate a number 
of commonly occurring variations, across the genome, each with relatively small effect 
sizes15, 17, 106, 133, 221. It is hypothesized that many idiopathic ASD cases, those with no 
diagnosed clinical syndrome, are a result of the interactions of multiple common 
variants, each with small to moderate effect sizes. Identifying common variation with any 
appreciable influence on ASD risk has proven difficult; however, this is not incredibly 
surprising, given the obvious complexity of ASD. Common variation associated and/or 
linked to ASD is discussed in greater detail in Chapter III. 
A large number of rare, recurrent, and non-recurrent mutations have been identified 
that are thought to lead to ASD34, 142, 162. Most of the identified rare mutations are small 
regions of chromosomal structural variation known as copy number variants (CNVs). 
Many of these CNVs have large effect sizes and some appear to be sufficient to cause 
ASD. Identified inherited CNVs, like those at 16p11 and 15q11-13, are transmitted from 
apparently unaffected parents, who may display some level of autistic traits, to affected 
offspring176. However, most identified CNVs are de novo events, arising in the germline. 
These de novo CNVs are reported in ~5–10% of ASD probands25, 156, 176, 177. Overall, 
CNVs are linked to a broad variety of clinical features, including severe neurological 
symptoms, severe ASD, milder autism-spectrum traits, and behavioral disorders outside 
of the autism spectrum160. Many CNVs found in ASD patients have also been found in 
patients specifically with intellectual disability and schizophrenia, but no ASD47, 162. 
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Phenotypic heterogeneity characterizing CNV expressivity makes it difficult to determine 
whether an identified CNV is the sole cause of autism, confers vulnerability to the 
disease, or represents a chance finding. It is also important to note that many de novo 
CNVs associated with ASD, while rare, are also observed in unaffected controls, 
suggesting these variations are not necessarily causal or fully penetrant34. Some CNVs 
may be acting as complex genetic risk factors, with intermediate effect sizes, variable 
penetrance and variable expressivity70.  
The current results from numerous genetic analyses in ASD all indicate an incredible 
complexity of underlying genetic mechanisms. However, the known biological functions 
for recurrently implicated genes suggest involvement of shared molecular pathways. For 
example, numerous genes have been identified that encode proteins important to 
synaptic function. These include neurologins and neurexins, specifically NLGN3, NLGN4 
and NRXN158, 98. Interactions between neuroligins and neurexins trigger the formation of 
functional pre-synaptic boutons46. Also included are post-synaptic scaffolding proteins, 
specifically SHANK1, SHANK2, and SHANK327, 203.  
Another convergent molecular mechanism in ASD is related to morphogenesis. 
Numerous protein-altering mutations and cytogenetic abnormalities have been identified 
that affect morphogenetic and growth-regulating genes. These genes include HOXA1, 
the first HOX gene to be expressed during embryogenesis which is necessary for the 
proper development of the brainstem, cerebellum and several cranial nerves42, 136, 208. 
Another implicated growth-regulating gene is EIF4E, the rate limiting component of 
eukaryotic translation initiation that plays a key role in learning and memory154. Finally, 
mutations disrupting the tumor suppressor gene, PTEN, have been identified in 
numerous patients with ASD. Most subjects with autism carrying PTEN mutations are 
characterized by severe to extreme macrocephaly35. 
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A collection of recent genetic evidence suggests that some ASD cases may result 
from abnormal Ca2+ homeostasis during neurodevelopment112. Several genetic studies 
have identified autism-related genes encoding ion channels, receptors, and Ca2+-
regulated signaling proteins, often times crucial to central nervous system development. 
These genes include, CACNA1C, CACNA1F, CACNA1H, KCNMA1, and SCN2A85, 117, 
198, 199, 222. 
Finally, the most consistently replicated genes harboring common variants related to 
ASD are: the SLC6A4 gene encoding the serotonin transporter, the EN2 gene, encoding 
the engrailed homeobox 2 protein (implicated in pattern formation during central nervous 
system development), the OXTR gene, encoding a G-protein coupled oxytocin receptor, 
the CNTNAP2 gene, encoding a neurexin family protein that functions in the nervous 
system, the GABRB3 gene, encoding a ligand-gated gamma-aminobutyric acid receptor, 
the RELN gene, encoding an extracellular matrix protein important for neuronal 
migration during development, the ITGB3 gene, encoding an integrin important in cell 
adhesion and signaling, and the MET gene, encoding the Met proto-oncogene involved 
in brain development160. 
 
Small Molecule Compound Treatment of Autism Spectrum Disorders 
There are currently no approved treatments for ASD as a whole, however, treatment 
regimens have been developed to address specific symptoms related to ASD. Atypical 
antipsychotics have been evaluated and approved for treating aggressive or self-
injurious behavior, severe mood swings, tantrums, and irritability in individuals with ASD. 
A commonly prescribed, and well-studied, atypical antipsychotic in ASD is risperidone180. 
The primary action of this molecule is serotonin 5-HT2 receptor blockade. It is also a 
potent dopamine D2 receptor antagonist
147. Selective serotonin reuptake inhibitors 
(SSRIs) are also often used for treating repetitive behaviors in ASD, and are known to 
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regulate peripheral and central nervous system serotonin levels110. SSRIs are effective 
in treating obsessive compulsive disorder in individuals without a diagnosed ASD39. 
However, current evidence suggests SSRIs, specifically citalopram (or escitalopram) 
and fluoxetine, are ineffective in treating restrictive repetitive behaviors in individuals with 
ASD110, 146. There has also been a recent push in the medical community to develop 
treatments that supplement endogenous molecules, like melatonin and oxytocin, shown 
to have dysregulated production in some ASD patients22, 137. Unfortunately, there is 
insufficient evidence supporting efficacy for most small molecule compounds used to 
treat ASD symptoms, and a large body of reported adverse events110, 146, 180. Further 
functional characterization of implicated genes and biological pathways are important 
avenues of research that will hopefully provide results helpful toward more effective 
personalized treatment of these psychiatric syndromes. 
 
All of the combined research in ASD highlights the incredible complexity of these 
disorders. It is difficult to identify unifying themes and establish reliable genotype-
phenotype relationships. The aim of this project was to overcome issues complicating 
identification and characterization of genetic factors involved in ASD. We attempted to 
minimize the effects of phenotypic heterogeneity, locus heterogeneity, epistasis and 
multiple genes conferring small effects to potentially increase power to detect genetic 
factors underlying ASD. To progress toward understanding how these significant genetic 
findings contribute to disease process and identify more effective treatments for ASD, 
further functional characterization of these associations is necessary. We attempted 
functional characterization of ASD-associated variation by screening a strongly 
implicated candidate gene for small molecule effects. This project has the opportunity to 
broadly impact the biomedical research community by contributing not only to ASD 
etiology and genetics, but also neurodevelopmental biology and pharmacogenetics. 
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CHAPTER II 
 
IDENTIFICATION OF GENETICALLY MEANINGFUL PHENOTYPIC SUBGROUPS IN 
AUTISM SPECTRUM DISORDERS 
 
Introduction 
 
As discussed in Chapter I, genetic factors have a strong influence on risk for Autism 
Spectrum Disorders (ASD)160. However, it has been difficult to identify individual, 
common genetic factors that replicate across multiple ASD cohorts, or confer large 
effects on risk15. A potential reason is that the wide variability in clinical manifestation 
can be explained by underlying genetic heterogeneity32, 70, 89. Identification of more 
phenotypically homogeneous subgroups of ASD may help account for this 
heterogeneity, allowing detection of genetic mechanisms conferring larger risk effects for 
specific ASD subgroups. 
Various attempts have been made to reduce heterogeneity in large-scale genetic 
studies of ASD. One approach is to separate individuals who meet Diagnostic and 
Statistical Manual-IV (DSM-IV) criteria for strict Autistic Disorder separately from those 
meeting only some criteria (i.e. DSM-IV Pervasive Developmental Disorder Not 
Otherwise Specified [PDD-NOS] or Asperger Disorder)12, 17, 123, 230. While this 
dichotomous categorization of ASD has advanced our knowledge of potential genetic 
risk factors, via detection of multiple statistically associated and/or linked chromosomal 
regions, it has still not implicated any genetic variants with large effects15. Further, family 
studies suggest that each of the behavioral domains underlying autism, including social 
impairment, communication impairment, and repetitive behavior, has separately 
inherited genetic risk factors that segregate in families44. Additionally, the change in 
criteria between DSM-IV and the new DSM-5 was motivated by the lack of empirical 
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data supporting separate disorders within the autism spectrum, highlighting the need for 
empirical approaches to identifying subphenotypes within ASD64, 192. 
Previous phenotype-focused studies have emphasized the importance of evaluating 
multiple sources of behavioral information when attempting to identify behaviorally 
defined subgroups within ASD65, 67, 122, 213. Multivariate statistical methods evaluating 
multiple sources of behavioral data have been used previously to identify between two 
and four defined subgroups within the broader classification of ASDs.  Categories used 
to distinguish these previously identified subgroups are severe, moderate and mild ASD, 
and severe intellectual disabilities53, 57, 164, 181, 187, 197, 201, 225. The most consistent findings 
across these different analyses are subgroups defined as either high- or low-functioning 
based on the level of symptom severity and some measure of intellectual capability. 
When age at exam is controlled for, fewer distinct clusters are identified and functional 
level (as indicated in these studies by nonverbal IQ, Wing Autistic Disorder Interview 
Checklist, Peabody Picture Vocabulary Tests, and VABS) stands out as a distinct 
identifier of subgroups57, 201. Despite these data, most studies have not evaluated 
whether or not there are specific genetic contributions to these phenotypic subgroups. 
One notable exception is a study where subsequent genetic analyses were performed in 
subgroups defined by cluster analysis88, 89, 91. Novel genetic factors were associated with 
distinct ASD subgroups, providing further support for phenotypic subgroups being 
genetically meaningful88. However, the cluster analysis used to define subgroups was 
limited to a single source of behavioral information, the ADI-R91. 
Many previous subgrouping efforts also lacked ascertainment of biomarkers or 
comorbidities commonly seen in ASD. As quantitative traits that are associated with ASD 
but not required for diagnosis, biochemical or anatomical biomarkers such as elevated 
whole blood serotonin levels or enlarged head size may improve our ability to identify 
more genetically homogeneous subgroups76, 89, 122, 214, 225. For example, multiple groups 
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have implicated the same chromosomal region, 7q35, and candidate gene, CNTNAP2, 
by refining phenotype definitions to include specific language impairment (SLI) in ASD, 
which parallels findings in isolated SLI6, 54, 161, 215, 223. With the DSM-5, SLI is removed 
from the ASD criteria and may therefore represent a comorbid diagnosis that is seen in a 
substantial minority of children with ASD, similar to other comorbid disorders like 
epilepsy209. 
We hypothesized that subgrouping cases using multiple sources of behavioral and 
biomarker data would create a more genetically meaningful phenotype definition and 
increase our power to detect genes influencing risk for ASD. We used novel applications 
of multivariate statistics to explore behavioral and clinical information from multiple 
sources. 
Methods 
 
Integrate Behavioral and Biomarker Data 
We included domain scores from the two main diagnostic instruments, the Autism 
Diagnostic Interview-Revised (ADI-R)128 and Autism Diagnostic Observation Schedule 
(ADOS)75, 127. Diagnosis-based studies find the greatest specificity when using both the 
ADI-R and ADOS in a multidisciplinary assessment process118. We also included scores 
from Vineland Adaptive Behavior Scales (VABS)193-195 for evaluation of intellectual and 
adaptive function, an important distinguishing factor in ASD28, 141. Ages at exam for all 
three instruments were included. Finally, we included the quantitative biomarker ‘head 
circumference’ (HC) as an indicator of either developmental or persistent macrocephaly. 
While macrocephaly is seen in the minority of adults with ASD, an increased rate of 
head growth during early childhood is noted in many children with ASD62, 213. 
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Multivariate Analyses 
We determined the correlation between phenotype traits in the discovery dataset 
using Spearman’s rank correlation coefficients. Since many variables are correlated, and 
discriminant analyses are extremely sensitive to variable input, we developed a 
weighting scheme (described below) for input variables based on the correlation 
structure to ensure that inter-correlated phenotype information did not overly influence 
the results. 
To understand the underlying phenotypic variability in the discovery dataset we 
performed a Principal Components Analysis (PCA)87. This analysis identifies the most 
important phenotypic traits in the data, simplifies the description of the dataset, and 
analyzes the structure of the observations and the input variables2. 
To define subgroups of phenotypic expression in the broader diagnostically-defined 
ASD dataset, we performed agglomerative hierarchical cluster analysis. This clustering 
method begins with each individual as a separate cluster and aggregates them back 
together using connectivity-based methods to evaluate the input data, effectively 
identifying groups of individuals having more similar measures across all input 
variables103. 
 
Dataset Demographics 
The discovery dataset consists of individuals from the Autism Genetic Resource 
Exchange (AGRE) family-based study71. Individuals not meeting DSM-IV criteria12 for an 
Autism Spectrum Disorder diagnosis on both the ADI-R and the ADOS were excluded. 
We also excluded individuals with potentially non-idiopathic autism (e.g. known 
neurogenetic disorders, known chromosomal abnormalities, prematurity <35 weeks). 
The final discovery dataset has 1,261 ASD cases, age at ADI-R 2-21 years old. The 
genetic ancestry as determined by the software program Structure165 is 73% European 
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American (EA), 17.8% Mexican American, 2.7% African American, and 6.5% unknown 
ethnicity due to missing genome-wide data. This dataset is 80% male and 95% of the 
cases are from multiplex families. 
The dataset we used for replication consists of individuals from the Autism Genome 
Project (AGP)92. This dataset is comprised of 2,563 ASD cases who are not present in 
the discovery AGRE dataset, meet DSM-IV criteria for a spectrum disorder on both the 
ADI-R and ADOS, and were 2-21 years old at the time of ADI-R. The genetic ancestry is 
64.6% European American, 3% Mexican American, 2% African American, and 30.4% 
unknown ethnicity due to missing genome-wide data. This dataset is 84% male and 54% 
of the cases are from multiplex families. The de-identified individual and family IDs for 
the final datasets are available in Appendix 1. 
 
Phenotype Data Comparisons 
We included social, communication, and restricted repetitive behavior (RRB) domain 
scores from both the ADI-R and ADOS. The communication measure for the ADI-R is 
divided into verbal and nonverbal scores. Since every person evaluated on the ADI-R 
receives a nonverbal score but not a verbal score and verbal and nonverbal 
communication scores are strongly correlated (ρ=0.86), we only incorporated the 
nonverbal scores in our analyses. We also included ‘abnormality of development evident 
at or before 36 months’ (DevAb) domain scores from the ADI-R. When available, domain 
standard scores for socialization, communication, daily living skills and motor skills were 
included from the VABS. Ages at exam for all behavioral tests were also incorporated 
into analyses. We evaluated head circumference (HC) z-scores taken at one time point. 
We generated z-scores for available HC measures by standardizing for age and sex 
using a normal population170. We excluded any HC measures taken when individuals 
were <1 month old. 25%-46% of the VABS and HC data were missing across the 
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datasets; however, the methods we used allow for and are robust to missing data (Table 
2.1).  
 
 
 
 
 
 
 
 
 
Traits included in our analyses represent different types of statistical variables, 
making direct comparisons difficult. The ADI-R is an interview given by a trained ASD 
specialist to caregivers of children and adults suspected of having an ASD. It probes for 
language, social, behavioral and functional abnormalities inconsistent with the 
individual’s current developmental stage. The ADI-R interview generates scores in each 
of three content areas: communication and language, social interaction, and restricted, 
repetitive behaviors. Item scores are measured on a finite ordinal scale. Increased 
scores indicate more severe abnormalities reported for the evaluated behaviors126, 128. 
Domain scores are calculated for all items assessing the behavioral characteristics 
relevant to ASD (social, communication, and restricted repetitive behaviors) and 
represent the sum of relevant item scores.  
Table 2.1. Availability of 
Phenotypes. Reported are 
percentage breakdowns of 
trait-specific information in 
both datasets. 
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ADOS is a semi-structured assessment of communication, social interaction and 
play, or imaginative use of materials, for individuals suspected of having autism or other 
pervasive developmental disorders127. Behavioral items relevant to ASD are scored on 
finite, ordinal scales, higher scores on these items indicate increased severity for 
abnormalities in the evaluated behavior75. Domain scores are calculated as described 
above for the ADI-R. ADOS domain scores were modified prior to percentile rank 
calculations to be comparable across the four possible modules by reducing raw ordinal 
values to that of the module with the smallest scale for each domain. For example, for 
ADOS modules 1, 3, and 4 communication is scored on an ordinal scale from 0-6, while 
for ADOS module 2 this measure is only scored on a scale from 0-4. Therefore, 
communication domain scores from modules 1, 3, and 4 were reduced to a scale of 0-4 
to make these scores more comparable to module 2. 
VABS focuses on social skills and is the measurement of adaptive behaviors, 
including the ability to cope with environmental changes, to learn new everyday skills 
and to demonstrate independence. This scale also yields composite and domain scores, 
however measured on a finite, continuous scale195. Increased scores on VABS 
measures indicate decreased severity for expression of evaluated traits. VABS data 
were ranked inversely to account for the inverse relationship of these severity scores 
when compared to the other diagnostic methods used in analyses. 
Head circumference z-scores and ages at exams represent continuous variables 
measured on an infinite scale. To allow more comparable measures, we chose to 
transform variables into Hazen percentile ranks using Stata 11.284, 200.  
We determined the correlation structure across all these variables by calculating 
pairwise Spearman’s rank correlation coefficients (ρ) (Stata 11.2) using all available 
percentile rank data. 
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Item-Level & Domain Score Comparisons: ADI-R & ADOS 
We chose to use domain scores, as opposed to item-level scores, from all evaluated 
behavioral instruments since these scores effectively cover information relevant to 
primary phenotype characteristics in ASD, and to minimize the potential for overfitting in 
our cluster analyses. Overfitting generally occurs when a model is excessively complex, 
such as having too many parameters relative to the number of observations. A model 
that has been overfit will generally have poor predictive performance, as it can 
exaggerate minor fluctuations in the data207. However, item level scores provide 
potentially genetically-relevant phenotypic information related to endophenotypes (i.e. 
savant skills)88, 89. To determine what information relevant to item-level scores were not 
covered by domain scores included in our analyses, we calculated percentile ranks for 
item-levels score from both instruments and determined the correlation across item 
scores and domain scores assessed on the same instrument. 
 
Principal Components Analysis (PCA) 
PCA was performed on percentile ranked data using the ‘FactoMineR’ package in 
R119. Variable weights were incorporated into PCA using the correlation structure 
observed in the dataset. We chose a threshold for independence at ρ<0.50. If a variable 
was correlated with another variable at ρ≥0.50 those variables were weighted to allow 
for only a partial variable contribution to PCA. Social and communication domain scores 
from the ADI-R were weighted such that these two scores together contributed one total 
variable weight in analysis. ADI-R RRB measures did not meet our threshold for 
correlation with any other variable and were therefore independent of other variables 
included in analysis. ‘Developmental abnormality evident prior to 36 months’ domain 
scores were also given one total variable weight. For the ADOS, we weighted social and 
communication domain scores together as one total variable contribution. The ADOS 
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RRB domain scores were weighted as an independent contribution. For the VABS, all of 
the domain standard scores were weighted as one total variable contribution. It is 
notable that the strongest correlations observed for the motor skills domain standard 
scores are with the communication domain standard scores at ρ=0.49, which did not 
quite meet our threshold for non-independence. However, the correlations observed by 
the VABS developers for the motor skills domain standard scores indicated dependence 
on the communication domain standard score (ρ=0.56-0.61)193. As such, we chose to 
incorporate only a partial weight for motor skills domain standard scores in our analyses. 
Head circumferences were given one total variable weight. Ages at exam for ADI-R, 
ADOS and VABS were weighted such that these three variables contributed one total 
variable weight. The cumulative number of variables incorporated into PCA using this 
weighting scheme equaled eight variables. We allowed up to 20 PCA dimensions to be 
retained in the results. 
 
Optimal Clustering Method and Dataset Partitions 
Dissimilarity matrices were calculated using the Gower dissimilarity measure from 
the ‘FD’ package in R, with variables weighted according to the weighting scheme 
described above for PCA115, 116. Seven different clustering methods were evaluated for 
internal validity while partitioning the dissimilarity matrix into anywhere from two to 15 
clusters using the ‘clValid’ package in R31. Evaluated clustering methods were kmeans, 
agglomerative hierarchical, model-based, partitioning around medoids, divisive 
hierarchical, self-organizing tree algorithm, and clustering large applications. 
To evaluate cluster validity, clValid calculates the Connectivity (an indication of the 
degree of connectedness of the clusters), Dunn index (a ratio of the smallest distance 
between observations not in the same cluster to the largest intra-cluster distance) and 
Silhouette Width (the overall average of the average distance between each observation 
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and others in the same cluster compared to different clusters). To evaluate cluster 
stability, clValid calculates the Average Proportion of Non-overlap (average proportion of 
observations not placed in the same cluster when variables are removed), Average 
Distance (average distance between observations placed in the same cluster when 
variables are removed), Average Distance between Means (average distance between 
cluster centers for observations placed in the same cluster when variables are removed) 
and Figure of Merit (average intra-cluster variance of the removed variable, where the 
clustering is based on the remaining variables)31. Sensitivity analysis was performed by 
removing one variable, reapplying weights to account for the missing variable, 
calculating a Gower dissimilarity matrix, clustering the data and calculating the above 
mentioned stability scores. This was done for each variable. 
 
Clustering and Cluster Validation 
Dissimilarity matrices were calculated as described above and variables were 
weighted according to the weighting scheme described above for PCA115, 116. The final 
agglomerative hierarchical clustering was performed on the Gower dissimilarity matrix 
using the ‘cluster’ package in R135. The agglomerative coefficient was calculated for the 
final clustering of the data. This represents a measure of all the individual dissimilarities 
calculated across the dataset and is an indication of the clustering structure identified103. 
This coefficient is measured on a scale from zero to one, zero indicating no clustering 
structure and one indicating complete structure. 
Validity of the final clusters was determined by permuting phenotype data across 
individuals, clustering the permuted data and calculating the Adjusted Hubert-Arabie 
Rand index (AHARI) to compare clustering of the real data to the permuted data94. This 
was done for 1,000 data permutations and the AHARIs were averaged. The 
permutations were accomplished by writing a function in R and the AHARI statistic was 
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calculated using a command from the ‘mclust’ package63. Sensitivity analyses were 
performed using the ‘clValid’ package in R, with slight modifications; weights were 
reapplied to account for variables removed and a Gower dissimilarity matrix was 
calculated prior to clustering31. Kruskal-Wallis tests were performed in STATA 11.2 on 
untransformed scores to determine the distributional variation of scores between main 
clusters and across subclusters. 
 
Genetic Contribution to Cluster Assignment 
Intra-cluster family structure was evaluated by calculating the odds of individuals 
being assigned to the same cluster given a familial relationship. We generated a 2X2 
contingency table and calculated an odds ratio via the chi-square statistic. ‘Case’ status 
was defined as a full sibling relationship and ‘exposure’ was defined as assignment to 
the same phenotype cluster. Each individual was manually scored for the number of full 
sibling relationships in the dataset. Since there are substantially more unrelated 
individuals than related in the datasets, we randomly sampled groups of unrelated 
individuals representing the same number of available familial relationships. We 
calculated an odds ratio for related ‘cases’ and each randomly sampled unrelated 
‘control’ group. This was done 10 times. The reported odds ratios represent the range for 
these calculations. We estimated genetic relationships using Single Nucleotide 
Polymorphism (SNP) markers previously genotyped in our datasets. Markers were 
pruned using genotyped founders based on linkage disequilibrium. We set an r2 
threshold of 0.16, within a 500 SNP window, sliding 5 SNPs at a time. We subsequently 
created a pedigree file of cases in our cluster dataset. Wright’s F-statistic (Fst) was then 
calculated using PLATO77. We grouped individuals into subpopulations based on cluster 
assignment. For each genetic marker, the correlation between individuals drawn from 
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the subpopulation relative to the total population was determined. We then took the 
average Fst calculated across the informative autosomal markers. 
 
 
Results 
 
Discovery Dataset (AGRE) 
Correlation Among Variables 
The correlation structure indicates diverse relationships among phenotype variables 
in the AGRE dataset (Fig. 2.1; Table 2.2). Social and communication scores measured 
on the same instrument are positively correlated (ρADI-R=0.62, ρADOS=0.57, ρVABS=0.80), 
while restricted and repetitive behavior scores are not strongly correlated with social and 
communication scores assessed on the same instrument (ρADI-R=0.07, 0.17; ρADOS=0.18, 
0.35). When comparing scores evaluating the same behavioral characteristic between 
the ADOS and ADI-R instruments, there is minimal correlation, especially with regard to 
RRB scores (ρSocial=0.37, ρCommunication=0.31, ρRRB=0.04). The strongest variable 
correlations across the ADI-R, ADOS and VABS are positive correlations between the 
social and communication scores from the ADI-R and VABS (ρ=0.45). The strongest 
correlation for the ‘developmental abnormality evident prior to 36 months’ scores from 
the ADI-R are a positive relationship with ADI-R social and communication domain 
scores (ρSocial=0.31, ρCommunication=0.29). Head circumferences are not strongly correlated 
with any of the behavioral measures. The strongest correlation for HCs is a positive 
correlation with VABS social and daily living skills domain standard scores (ρ=0.14). As 
expected, ages at exam are strongly correlated across the ADI-R, ADOS and VABS 
(ρ=0.84-0.94). 
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Table 2.2. Spearman’s Correlation Coefficients. Spearman’s rho correlations 
calculated in AGRE discovery dataset. Comm=Communication Domain Scores; 
RRB=Restricted, repetitive behaviors; DevAb=Abnormality of Development evident 
≤36 months; MS=MotorSkills; DL=Daily Living; HC=head circumferences. 
Figure 2.1. Variable Correlation Structure in Discovery Dataset. Plot of Spearman’s 
correlation coefficients used in variable weighting scheme for PCA and clustering. 
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Item-Level & Domain Score Comparisons: ADI-R & ADOS 
Spearman’s correlation coefficients indicate that for the ADI-R, the domain scores we 
included in analyses do not provide information relative to presentation of savant skills, 
acts of aggression, or hyperactivity (Fig 2.2a). Domain scores from the ADOS do not 
provide information relative to speech abnormalities associated with ASD, anxiety, 
aggressive tendencies, or hyperactivity (Fig 2.2b). 
Figure 2.2. Correlation Across Domain and Item Scores. Plot of Spearman’s 
correlation coefficients showing correlation across domain scores used as variable input 
(indicated by stars) and item-level information not included in domain score calculations 
for a. ADI-R and b. ADOS. 
21 
 
Principal Components Analysis 
PCA identifies15 components comprising the data, with 53% of the phenotypic 
variance being explained by the first three components and the remainder of the 
variance being explained in increasingly smaller increments from components four to 15 
(Fig. 2.3). Principal component (PC) one defines 25% of the phenotypic variance in the 
discovery dataset. Although most input variables contribute to the phenotypic variance 
defined in PC1, the two variables with the strongest contributions are ADOS RRB scores 
and ADI-R DevAb scores (Table 2.3). HC, ADI-R RRB scores and ages at exam do not 
have strong contributions to PC1. However, these variables explain the majority of the 
phenotypic variance defined by PC2 and PC3. These two components combined explain 
another 29% of the phenotypic variance in the discovery dataset (PC2≈15%, PC3≈14%). 
PC4 defines another 11% of the phenotype variation in the dataset. Similar to PC1, the 
two variables contributing most to the phenotypic variance defined in PC4 are ADI-R 
DevAb scores and ADOS RRB scores. However, unlike PC1, the next strongest 
contributors are RRB scores from the ADI-R. Social and communication scores from the 
ADI-R and ADOS, and scores from the VABS have much smaller contributions to PC4 
than to PC1. PC5 defines 9% of the variance in the data and has strong contributions 
from HCs, DevAb scores and RRB scores from the ADI-R. PC6 defines another 7.5% of 
the variance in the dataset with ADOS RRB and communication scores contributing to 
over half of this defined variance. PC7 defines another 5.5% of the phenotypic variance; 
its strongest contributors are measures from the VABS and ADOS communication 
scores. PC8 defines another 5% with the strongest contributors being ADI-R social and 
communication scores closely followed by these same scores from the ADOS. The 
combined phenotypic variance explained in the AGRE dataset by the first 8 principal 
components is 91.5%. The remaining principal components, PC 9-15, each define very 
small portions of the phenotypic variance observed in the data (0.35%-2.5%) and 
22 
 
Figure 2.3. Phenotype Variance Explained by Principal Components. Plotted are the 
percentages of phenotypic variance explained, based on eigenvalues, by each Principal 
Component defined in the AGRE dataset. 
combined explain the remaining 8.5% of phenotypic variance in the dataset. The 
variables contributing the most to these final seven PCs are further outlined in Table 2.3. 
Table 2.3. Variable Contributions to Principal Components of AGRE Dataset. 
Variables contributing the most to the observed variance explained by each component 
are indicated in bold italics. 
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Clustering 
PCA helped to define the underlying phenotypic variability in the dataset and identify 
the most important classifying variables, but did not clarify the phenotypic nature of each 
subgroup of cases. Unsupervised clustering was therefore performed to define ASD 
subgroups and obtain a broader sense of the phenotype characteristics of these 
subgroups. The overall best validity scores were calculated when using agglomerative 
hierarchical clustering to group the AGRE dataset into two clusters. The next best 
validity scores were calculated when using agglomerative hierarchical clustering to 
subgroup the dataset into 10 subclusters (Table 2.4). 
Following agglomerative hierarchical clustering, we grouped the data into the most 
valid partition (i.e. two major clusters), one cluster with 443 cases and one cluster with 
818 cases (Fig. 2.4). The agglomerative coefficient calculated for clustering of the AGRE 
dataset is 0.78, evidence that a strong clustering structure was identified. We evaluated 
phenotype variable distributions between the two main clusters. Kruskal-Wallis tests 
show that all variable distributions, except ADI-R RRB and HC, are significantly different 
(p<0.0001) between these clusters (Table 2.5). Examination of the summary statistics for 
phenotype variables by cluster show that individuals with scores indicating more severe 
measures for most variables are placed into the larger cluster, referred to as ‘more 
severe’, when compared to the smaller cluster, referred to as ‘less severe’ (Table 2.6). 
The two main clusters could then be grouped into 10 subclusters; the ‘more severe’ main 
cluster grouped into six subclusters and the ‘less severe’ main cluster grouped into four 
subclusters. Phenotype variable distributions were then evaluated across the 10 
subclusters. Kruskal-Wallis tests show that the previously non-significant ADI-R RRBs 
and HC are very different (p<0.0001) across the 10 subclusters. HC distributions are 
statistically different across the four subclusters comprising the ‘less severe’ main cluster 
(p=0.0034) and the six subclusters comprising the ‘more severe’ main cluster 
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(p<0.0001). ADI-R RRB score distributions are also statistically different between the 
four subclusters comprising the ‘less severe’ main cluster (p<0.0001) and the six 
subclusters comprising the ‘more severe’ main cluster (p<0.0001). The average Adjusted 
Hubert-Arabie Rand index (AHARI) calculated over 1,000 data permutations shows that 
partitioning of real data for the discovery dataset is significantly different than partitioning 
permuted datasets (AHARI=-6.14x10-5). 
Sensitivity analyses show that ADI-R DevAb scores have the overall largest effect on 
main cluster stability. Communication scores from the ADOS and social, communication 
and daily living domain standard scores from the VABS appear to have the least effect 
on main cluster stability. The remaining input variables have similar and modest effects 
on main cluster stability. Regarding the subclusters, with the exception of the DevAB 
scores from the ADI-R, removal of any other input variable has similar and minor effects 
on subcluster stability (Table 2.7). 
Familial relationships are significantly associated with assignment to the two main 
phenotype clusters (OR≈1.38-1.42, p<0.00001). Wright’s F-statistic indicates that 
genotype frequencies are more similar within clusters than in the entire unclustered 
dataset (Average Fst≈0.17) (Table 2.8). 
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Table 2.5. Cluster Differences 
in the AGRE Dataset. Kruskal 
Wallis comparisons of variable 
distributions between the two 
main clusters and across the ten 
subclusters. All input variable 
distributions, except ADI-R RRB 
and HC, are significantly 
different between the main 
clusters. ADI-R and HC 
distributions are significantly 
different across subclusters. 
Asterisks indicate information 
not used as input variable. 
Table 2.6. Summary Statistics for Unclustered vs Clustered AGRE Datasets. 
Reported are medians and modes observed in the unclustered dataset compared to 
the two main clusters. Continuous variables are starred to indicate that the mean is 
reported in place of the median. Cases with scores indicating increased ASD severity 
preferentially cluster into the second, larger cluster. Age is reported in years. 
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Replication Dataset (AGP) 
We tested for replication in the independent, non-overlapping Autism Genome 
Project dataset. We see a similar correlation structure among AGP dataset phenotype 
input variables as in the AGRE dataset (Table 2.9). Using the same correlation threshold 
(ρ≥0.50), we incorporated the same eight variable weighting scheme in subsequent PCA 
and clustering analyses. To define the phenotypic variance, PCA again identified 15 
components. Most input variables contribute similarly to phenotypic variance explained 
in PC1, with the exception of HC, ADI-R RRBs, ages at exams and VABS motor skills 
having little contribution. HC, ADI-R RRB and ages explain the majority of the 
phenotypic variance defined by PC2 and PC3. Combined, PCs 1-3 define ~50% of the 
phenotypic variance in the data. Further details on variable contributions to all 15 data 
Table 2.7. Sensitivity Analyses. Reported are results from sensitivity analyses. For 
the stability measures calculated, smaller values indicate more stable cluster results. 
Statistics evaluating cluster stability upon removal of each variable are: APN=Average 
proportion of nonoverlap or number of individuals not placed in same cluster when 
variable is removed (scale=0,1); AD= Average distance between individuals placed in 
same cluster when variable is removed (scale=0, ∞); ADM=Average distance between 
means between cluster centers for individuals  placed in same cluster when variable is 
removed (scale=0, ∞); FOM=Figure of merit or average intra-cluster variance of the 
removed variable where clustering is based on remaining variables (scale=0, ∞). 
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components are outlined in Table 2.10.  Again, the optimal clustering method 
determined to group the AGP dataset was determined to be agglomerative hierarchical 
(Table 2.11). This method validly grouped the AGP dataset into two main clusters and 
15 subclusters (Fig. 2.5). Kruskal-Wallis tests show that most input variable distributions 
are significantly different between the two main clusters (p<0.0001), with the exception 
of HC (Table 2.12). However, the distributions of HC are significantly different across the 
15 subclusters (p=0.0020). HCs are statistically different between the six subclusters 
comprising the ‘less severe’ main cluster (p=0.0007) but not the nine subclusters 
comprising the ‘more severe’ main cluster (p=0.37). Cases with increased severity 
measures for most variables tended to group into the larger main cluster (n=1,527) 
compared to the smaller main cluster (n=1,036) containing cases with generally less 
severe scores for the majority of variables (Table 2.13). The agglomerative coefficient 
calculated for clustering of the AGP dataset is 0.79, indicating strong hierarchical 
clustering structure. The AHARI statistic shows that clustering of the real phenotype data 
is significantly different than permuted datasets (AHARI=-4.10x10-6). 
Sensitivity analyses again show that ADI-R DevAb scores have the overall largest 
effect on main cluster stability. The remaining input variables have similar and modest 
effects on main cluster stability. Regarding the subclusters, removal of any input variable 
has similar effects on subcluster stability (Table 2.14). 
In the AGP dataset, we again see that given a full sibling relationship, cases have 
increased odds of going into the same main cluster (OR≈1.19-1.35, p<0.00001) and that 
clusters contain individuals with more similar genotype frequencies than the unclustered 
dataset (Average Fst≈0.13) (Table 2.8). 
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Table 2.8. Results Evaluating Genetics Underlying Cluster Assignments. a. Odds 
Ratios represent increased odds of cases being assigned to the same cluster given a 
familial relationship. b. Average Wright’s F-statistic (Fst) across informative autosomal 
markers comparing cluster subpopulations to total unclustered population. Fst 
reported for the entire clustering dataset and the European Americans (EA) only. 
Frequency (f) of full sibling relationships in main clusters used for odds ratio 
calculations are: fAGRE=0.91; fAGP=0.38. 
cluster.  
Table 2.9. Variable Contributions to Principal Components of AGP Dataset. 
Variables contributing the most to the observed variance explained by each component 
are indicated in bold italics. Comm=Communication Domain Scores; RRB=Restricted, 
repetitive behaviors; DevAb=Abnormality of Development evident ≤36 months; 
MS=MotorSkills; DL=Daily Living; HC=head circumferences. 
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Table 2.10. Variable Contributions to Principal Components of AGP Dataset. 
Variables contributing the most to the observed variance explained by each component 
in the AGP dataset are indicated in bold italics. 
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Table 2.12. Cluster 
Differences in AGP Dataset. 
Kruskal Wallis comparison of 
variable distributions between 
the two main clusters and 
across the 15 subclusters. All 
input variable distributions, 
except HC, are significantly 
different between the main 
clusters. HC distributions are 
significantly different across 
subclusters. Asterisks indicate 
information not used as input 
variable. 
Table 2.13. Summary Statistics for Unclustered vs Clustered AGP Datasets. 
Reported are medians and modes observed in the unclustered dataset compared to 
the two main clusters. Continuous variables are starred to indicate that the mean is 
reported in place of the median. Cases with scores indicating increased ASD severity 
preferentially cluster into the second, larger cluster. Age is reported in years. 
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Discussion 
 
The extensive phenotypic variability within ASDs may hinder our ability to identify 
genotype-phenotype associations. To address this problem, we used multivariate 
statistical analyses to take advantage of ASD-related behavioral information from 
multiple sources and to include quantitative data relevant to macrocephaly. This 
approach allows effective evaluation of a broad array of data, enabling potentially more 
accurate phenotype definitions for large ASD datasets. We demonstrate that ASD 
phenotypic subgroups exist and can be replicated. Further, we demonstrate that these 
subgroups are genetically relevant. 
Table 2.14. Sensitivity Analyses: AGP Dataset. Reported are results from 
sensitivity analyses. For the stability measures calculated, smaller values indicate 
more stable cluster results. Statistics evaluating cluster stability upon removal of each 
variable are: APN=Average proportion of nonoverlap or number of individuals not 
placed in same cluster when variable is removed (scale=0,1); AD= Average distance 
between individuals placed in same cluster when variable is removed (scale=0, ∞); 
ADM=Average distance between means between cluster centers for individuals  
placed in same cluster when variable is removed (scale=0, ∞); FOM=Figure of merit 
or average intra-cluster variance of the removed variable where clustering is based 
on remaining variables (scale=0, ∞). 
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Optimal Clustering Method 
It is interesting that the optimal clustering method used to evaluate the ASD data is 
the agglomerative hierarchical method. This method uses connectivity based clustering 
and is unique from other methods because it begins with each individual as a separate 
cluster and aggregates them back together using the variable dissimilarities calculated 
for each individual when compared to every other individual103. It may be then for very 
complex traits, like those seen impaired in ASD, initially focusing on similarities across 
the dataset instead of differences will lead to identification of traits having the largest 
effect on variation overall. 
 
Phenotype Clusters 
The strongest and most obvious clustering aggregates ASDs into two major clusters, 
grouped on overall symptom severity. When comparing variable distributions between 
the unclustered AGRE and AGP datasets, we observed that the two datasets had 
significantly different distributions of family structure and gender. The AGRE dataset 
having proportionally more females (z=3.41, p=0.003) and multiplex families (z=21.67, 
p<0.00001) than the AGP dataset. Previous research has suggested that phenotypic 
expression of ASD in multiplex families is distinct from that in simplex families216. There 
is also previous evidence indicating sex-specific effects in ASD54. It is striking that given 
these initial differences between datasets, our approach still identified main clusters with 
similar characteristics. In fact, some input variable distributions that were significantly 
different between the unclustered datasets were no longer significantly different when 
comparing distributions in the similarly-defined main clusters from both datasets (i.e. 
AGRE "less severe" and AGP "less severe") (Table 2.15). The initial differences 
between the AGRE and AGP datasets may account for the resulting subclusters being 
not as easily comparable (Table 2.16). Even with the different variable distributions we 
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observe when comparing the subclusters from both datasets, there are some interesting 
similarities. For instance, at this level of subclustering we observe very small groups of 
cases that are remote from the other larger subclusters. In the AGRE dataset, we 
observe one small subcluster (n=47) within the ‘less severe’ main cluster, and three 
small subclusters (n=10, 38, 38) within the ‘more severe’ main cluster. The commonality 
across each of these smaller subclusters is that assigned individuals have large 
discrepancies between comparable domain scores (e.g., communication domain) from 
the ADI-R and ADOS. For example, individuals have either more severe scores on the 
ADI-R domains and less severe scores on the ADOS domains, when compared to larger 
subclusters within the same main cluster, or vice versa even though the ages at exam 
for both instruments are very similar. We see similar outlier groups in the AGP dataset 
subclusters.  
 
 
 
 
 
 
 
 
Table 2.15. Dataset Differences. Kruskal Wallis comparisons of variable 
distributions between the AGRE and AGP datasets, as well as the resulting clusters. 
Particularly, ADI-R social scores, and ADI-R & ADOS RRB scores are more 
divergent between the two datasets than the comparable main clusters. 
Unclustered=AGRE vs. AGP dataset; “Less Severe”=“less severe” AGRE cluster vs. 
“less severe” AGP cluster and similar for the “more severe” clusters. Asterisks 
indicate information not used as input variable. 
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With the exception of these small outlier subclusters, it is apparent that age ranges 
are much smaller within subclusters when compared to main clusters. In both the AGRE 
and AGP datasets, there is one subcluster grouped separately from the other 
subclusters within the ‘more severe’ main cluster that contains some of the youngest 
individuals in the datasets ( AGRE_ADI-R=6.6 years, 95%CIAGRE_ADI-R=6.3-6.9, nAGRE_ADI-
R=416; AGP_ADI-R=5.7 years, 95%CIAGP_ADI-R=5.4-6.1, nAGP_ADI-R=277). In the AGRE 
dataset there are also two subclusters within the ‘more severe’ main cluster that include 
a majority of nonverbal individuals (61%-63% nonverbal) when compared to other 
subclusters within the ‘more severe’ main cluster (0-18% nonverbal) and the subclusters 
comprising the ‘less severe’ main cluster (6%-14% nonverbal). We also see two similar 
subclusters within the ‘more severe’ AGP dataset cluster (61%-64% nonverbal). 
We see that scores assessing similar ASD traits do not correlate strongly between 
the ADI-R and ADOS, especially with regard to the RRB measure, even though all 
individuals evaluated meet ASD diagnostic criteria on both instruments. Our 
observations of weaker correlations for the RRB measures are also consistent with other 
Table 2.16. Subcluster 
Differences between Datasets. 
Kruskal Wallis comparisons of 
variable distributions across 
subclusters from both datasets. 
All input variable distributions are 
significantly different among the 
subclusters when comparing 
these groups between the AGRE 
and AGP datasets. “Less Severe” 
= Subclusters within the “less 
severe” main clusters compared 
between datasets and similar for 
the “more severe” subclusters. 
Asterisks indicate information not 
used as input variable. 
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studies where weaker correlation was observed between the ADI-R and ADOS repetitive 
behavior scores compared to the social and communication scores118. Previous studies 
have also shown that the ADI-R and ADOS make independent, additive contributions to 
more accurate diagnostic decisions and that specificities improve significantly when both 
instruments are used compared to each alone105. Our results provide further evidence 
that including information from both tests is important for precise definition of ASD 
phenotypes. 
 
Effect of Developmental Abnormality Measure 
All variables included as input in our multivariate analyses influence PCA results and 
cluster assignment. However, the ‘severity of abnormalities related to ASD behavioral 
criteria exhibited by 36 months of age’ (DevAb) score from the ADI-R stands out as 
having a stronger influence on cluster and PCA results. This measure is used in 
diagnosis in the ADI-R, based on criteria established by the DSM-IV. There must be 
evidence of deficient social or communication skills prior to or by 36 months for a 
diagnosis of strict autism to be made128. We see that this measure from the ADI-R does 
not exhibit strong correlations with any other input variable and has a substantial 
influence on the phenotypic variance explained in the first PC of both datasets. This 
measure has consistently different distributions between clusters and across subclusters 
and the largest overall effect on cluster and subcluster stability. In both the discovery 
and replication datasets, we see in the resulting ‘more severe’ clusters that 59-80% of 
individuals received the highest score possible for this measure indicating very severe 
abnormality of development observed early in life, compared to 0-0.4% of individuals in 
the ‘less severe’ clusters. 
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Effect of Repetitive Behavior Measures 
Repetitive behaviors also stand out from other variables in their contribution to the 
phenotypic variance explained in the first three PCs of both datasets. ADOS RRB 
measures have a strong contribution to the first data component, and consequently have 
significantly different score distributions between individuals in the two main clusters. 
Interestingly, ADI-R RRB measures are not strong contributors to the first PC of the 
AGRE dataset. However, ADI-R RRB measures do have strong contributions to PC2 
and PC3. In the AGP dataset, the contribution from these measures to PC1 is more 
comparable to other input variables. Yet, ADI-R RRB scores still do not contribute as 
much to PC1 as do RRBs assessed with the ADOS. This is also apparent in the 
clustering results; ADI-R RRBs are not significantly different between the two main 
AGRE dataset clusters but are significantly different between the two main AGP dataset 
clusters. These scores also have significantly different distributions across the 
subclusters from both datasets. It is interesting that RRB measures have different levels 
of influence on both phenotypic variance defined via PCA and definition of the two main 
clusters, based on whether they are evaluated with the ADOS or the ADI-R. 
One explanation for the differing influence of RRBs on multivariate statistical results 
when comparing diagnostic instruments is that RRBs are not as extensively evaluated 
with the ADOS as with the ADI-R. RRBs observed on the ADOS are more likely to be 
simple repetitive behaviors that are easily observed in a brief interaction. Many RRBs 
are difficult to assess in a short period of time because certain restrictive and repetitive 
behaviors may only occur in specific situations, and the ADOS is limited by both time 
and context95. In contrast, the ADI-R captures a broader array of RRBs and provides 
information for more complex repetitive behaviors. It is notable that by including ADI-R 
domain scores and not item level scores we are not fully distinguishing simple versus 
complex repetitive behaviors. 
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An explanation for the differing influence of ADI-R RRBs on multivariate statistical 
results when comparing datasets is that the AGP dataset has more than twice the 
number of individuals with this information than does the AGRE dataset. Since the ADI-
R is useful for distinguishing types of RRBs, it may be necessary to have more data from 
individuals exhibiting similar RRB characteristics for this measure to have an appreciable 
impact on main cluster assignment. Even with this difference, ADI-R RRB scores are 
more noticeably distinct across the subclusters when compared to the main clusters 
from both datasets. 
The combined evidence from PCA and agglomerative hierarchical clustering suggest 
that presence of RRBs is important to ASD phenotype definitions in these datasets and 
that this behavior is unique from the social and communication deficits for definition of 
ASD subphenotypes. This is in line with numerous previous studies29, 36, 82, 95, 138, 163, 172, 
173, 182, 188. There is also evidence that ADI-R RRB scores have the strongest within-
family concordance when compared to the social and communication measures 
providing support for a uniquely inherited component197. 
 
Effect of Head Circumference 
Head circumferences do not contribute significantly to the phenotypic variance 
observed in the first principal component of either dataset, which by design defines more 
variance than any other PC87. We also see that the distributions for this measure are not 
significantly different between the two main clusters grouped by overall ASD severity. 
We do, however, see a substantial contribution to the definition of phenotypic variance 
explained by the third PC of the AGRE dataset and the second PC of the AGP dataset, 
and HCs do seem to have a strong influence on subcluster assignment. However, in the 
AGRE dataset HCs are significantly different across the subclusters regardless of main 
cluster assignment whereas in the AGP dataset, HCs are only significantly different 
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across the subclusters comprising the less severe main cluster. We were surprised that 
head circumference did not have a stronger influence on main cluster assignment, AGP 
subcluster assignment, and definition of PC1. It is notable that for both evaluated 
datasets, the mean normalized HC is above average compared to individuals not 
diagnosed with a spectrum disorder ( AGRE=0.72, AGP=0.66). It is possible that most 
individuals with ASD have larger head circumferences compared to normal individuals 
and that this is not a distinguishing trait for ASD subgroups but rather a trait specific to 
the broader diagnostic classification. Macrocephaly roughly defined as >2 standard 
deviations above the mean is only comorbid in ~13% of individuals for which this 
measure is available, in both the AGRE and AGP datasets. These rates are slightly 
lower than expected based on previously reported estimates ranging from 15-35%62, 227. 
This is consistent with other observations indicating individuals with ASD have increased 
head growth but do not meet criteria for macrocephaly. Unfortunately, HC measures are 
only available for ~54% of the AGRE dataset and ~47% of the AGP dataset. This could 
also be an explanation for the observed impact of HC on cluster assignment and the 
lower rate of macrocephaly in the AGRE and AGP datasets.  
Another important caveat to our evaluation of head circumference is that ethnicity is 
noted to be important in head circumference normalization227. We normalized HC 
measures using a non-diseased population of European descent, due to our inability to 
identify normal population statistics for other ethnicities of interest with a similar age 
range to the datasets evaluated in our study. Our datasets have a slightly different ethnic 
background than does the normal population we used to normalize HC and this could 
affect our z-score calculations. We also did not take into account height, another factor 
that should be considered when evaluating macrocephaly, since this information is 
available for even fewer individuals in the AGRE and AGP datasets (~29% and ~46%, 
respectively). Height and head circumference measures, when available in our datasets, 
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Figure 2.6. Correlation of Head Circumference & Height in Evaluated Datasets. 
Plotted are head circumferences (cm) versus height (cm) for individuals in the a. AGRE 
dataset and b. AGP dataset. Reported are squared Pearson's correlation coefficients (r2). 
do exhibit positive correlations suggesting the increased HC may be due to increased 
stature and not necessarily exhibition of an endophenotype (ρAGRE=0.66; ρAGP=0.44) 
(Figure 2.6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The combined results from PCA and clustering indicate HC is important in defining 
ASD subphenotypes, but not in determining overall severity. Again, these measures are 
not available for a large portion of the cases in the datasets we evaluated, which could 
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affect the variable’s impact on definition of PC1 and main clusters even with our 
stringent weighting scheme and the ability of the methods to allow for missing data. The 
same is also true for Vineland domain standard scores. While these scores do seem to 
be involved in definition of the main clusters, they do not contribute greatly to PC 
definition or stand out as classifying variables. These findings are possibly a result of 
having fewer individuals with VABS scores compared to ADI-R and ADOS scores. We 
chose to retain cases that are missing VABS and HC information since these are not 
considered ASD-specific diagnostic criteria. 
 
Familial Clustering 
Odds ratios showed significantly increased odds for affected siblings to cluster 
together into the two main clusters when compared to unrelated cases. These 
calculations are indicative of underlying genetic architecture. Further supporting this 
assumption, Wright’s Fst calculations suggest cases with more similar genetic 
architecture clustered together into the two main clusters. Although Fst can be 
confounded by genetic ancestry, we obtained similar results using only individuals with 
European ancestry. It is notable that there is still evidence for significant genetic and 
phenotypic heterogeneity within ASD families. This is in agreement with many previous 
studies and the growing body of evidence reporting the involvement of de novo 
mutations arising in the germ-line25, 176, 177. However, the relationship of genotype to 
phenotype should be somewhat independent of inheritance patterns. While our results 
supported an underlying genetic influence on overall cluster assignment, to determine 
the true contribution of genetic factors to phenotypic cluster assignment it will be 
necessary to perform future genetic analyses based on these cluster groupings. 
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The overlapping interpretation of our results from two different multivariate analyses, 
PCA and clustering, demonstrate the utility of this approach. That we were able to show 
defined subgroups of phenotypic expression appearing to be genetically meaningful in 
the AGRE dataset and replicate these findings in an independent AGP dataset lends 
further support to the validity of the resulting cluster groupings and the idea that the 
phenotype clusters recapitulate underlying genetic mechanisms in Autism Spectrum 
Disorders. 
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CHAPTER III 
 
PATHWAY-BASED GENOME-WIDE ASSOCIATION STUDIES IN DEFINED 
SUBGROUPS 
 
Introduction 
 
Genetic factors have a strong influence in the etiology of ASD. However, the 
individual effects of most previously implicated common variants are modest, tend not to 
replicate in independent cohorts, and the combined evidence from many analyses does 
not explain the estimated heritability21, 44, 45, 79, 159. The difficulty in identifying common, 
inherited variation with replicable effects may arise from the wide variability in clinical 
manifestation of ASD and the relationship to genetic influences. 
Evaluating larger sample sizes is one way to increase power in genetic studies of 
complex disorders, like ASD56. Studies have been conducted in large ASD cohorts when 
the phenotype is categorized dichotomously (i.e., affected/unaffected) by diagnostic cut-
offs17, 123, 230.  However, none of these associations replicate in independent cohorts, 
suggesting an increase in sample size is not sufficient to optimize power for ASD. It is 
also difficult to interpret potential phenotype-genotype relationships using results from 
these large-scale genetic analyses since evaluated cases express a wide continuum of 
symptom severity. 
Previous studies have defined more phenotypically homogenous subgroups in ASD 
using overall trait severity, endophenotypes, and comorbidity information and evaluated 
genetic contributions to these subgroups7, 24, 88, 90, 179, 183, 184, 204. In numerous cases, 
linkage and association signals were increased despite a substantial reduction in sample 
size. Many of these studies also replicate previous results from analyses performed 
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when subphenotypes of ASD were further defined8, 40, 130. These studies provide strong 
support for phenotypic subgroups being genetically meaningful. 
Factors further complicating genetic association studies in ASD are related to the 
complexity of the underlying genetic models of the disorder. There are hundreds of 
different genes and risk loci implicated in ASD etiology26, 143, 157. Few, if any, of the 
currently identified genetic factors alone seem to contribute strong effects (OR>1.2) to 
risk for ASD16, 50. These smaller effects are easily overlooked in the typical approach to 
analysis of GWAS data, which looks for the most significantly associated individual 
single nucleotide polymorphisms (SNPs). Evidence from multiple independent studies 
indicates common, inherited variants have a cumulative effect on ASD risk68, 107, 168. In 
reality, genes often work as complex interacting networks, especially those involved in 
neural development. Pathway-based analysis of genome-wide SNP data considers the 
combined effects of multiple genetic variants functioning together in biological 
pathways155, 218.  By applying this methodology to analysis of ASD genetic data, causal 
pathways and/or genetic interactions may be implicated giving biological insights that 
would otherwise be imperceptible18, 86, 121, 132, 158. 
Our hypothesis is that performing pathway-based genetic analyses in more 
phenotypically homogeneous ASD subgroups accounts for some heterogeneity, thus 
increasing power to detect genetic effects. We previously performed extensive 
phenotypic analyses in an Autism Genetic Resource Exchange (AGRE)72 dataset212. We 
used data from the Autism Diagnostic Interview-Revised (ADI-R)128, Autism Diagnostic 
Observation Schedule (ADOS)127, Vineland Adaptive Behavior Scales196, head 
circumferences, and ages as classifying variables. Unsupervised clustering identified 
two distinct groups of cases, dividing primarily on the severity of phenotypes. The same 
approach similarly identified two distinct groups of cases and confirmed this severity-
based dichotomy in an independent dataset from the Autism Genome Project (AGP)93. 
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In addition, there was significant familial clustering within groups (OR≈1.38-1.42, 
p<0.00001), suggesting that the clusters recapitulated genetic etiology. Identifying 
biological pathways and sets of genes contributing to the underlying mechanisms 
involved in expression of subphenotypes of ASD will help us gain further insight into the 
functional foundations of the various phenotypic aspects of this disorder. This study is 
one of the first to apply pathway analysis to ASD GWAS data, and to apply this 
methodology to well-defined subgroups of affected individuals. 
 
Methods 
 
Dataset Demographics and Quality Control 
The discovery dataset consisted of individuals from the AGRE family-based study. 
We used previously generated, publicly available genetic data; samples were genotyped 
on the Illumina Bead Array and Affymetrix 550 chip134. Genetic data were merged in 
PLINK166 and the final merged datasets were subjected to numerous quality control (QC) 
procedures (Figure 3.1). The final discovery dataset included 4,110 individuals (2,559 
males and 1,551 females) in 895 families. 91.2% of these families were multiplex, 8.6% 
were simplex, and 0.2% had unknown family structure. Genetic ancestry determined by 
the software program Structure165 was 80.1% European American, 16.2% Mexican 
American, 2.8% African American, and 0.8% mixed ancestry. After QC, a total of 
507,669 SNPs, with a genotyping rate of 99.4%, were analyzed in discovery association 
analyses. 
For the validation dataset, we used samples from the AGP database. Samples were 
previously genotyped on the Illumina 1M platform134. The same QC procedures used on 
genotyping data from the discovery dataset were used for the validation dataset. The 
final validation dataset contained 8,908 individuals (5,475 males and 3,275 females) in 
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2,960 families. 31% of the families in the validation dataset were multiplex, 49% were 
simplex families, and 20% of the dataset had unknown family structure. Genetic ancestry 
was 91.4% European American, 5.8% Mexican American, 2.6% African American, 0.2% 
mixed ancestry. After QC, a total of 779,343 SNPs with a genotyping rate of 99.8%, 
were analyzed in validation association analyses. 
 
Single-SNP Association Analyses: AGRE Dataset 
We used the AGRE family dataset for our initial modeling.  Exclusion criteria and 
affection status for association analyses were selected based upon phenotype analyses 
described in detail in Chapter II. Briefly, cases meet Diagnostic and Statistical Manual-IV 
(DSM-IV) criteria for an Autism Spectrum Disorder diagnosis on both the Autism 
Figure 3.1. Quality Control Procedures. Outlined is a flow diagram detailing exclusion 
criteria used to obtain quality genotyping data for AGRE discovery analyses and the 
final number of evaluated SNPs and samples. Marker exclusion criteria are detailed on 
the left and sample exclusion criteria are detailed on the right. 
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Diagnostic Interview-Revised128 (ADI-R) and the Autism Diagnostic Observation 
Schedule127 (ADOS), age at ADI-R 2-21 years old. We excluded individuals with 
potential non-idiopathic autism (e.g. known neurogenetic disorders, known chromosomal 
abnormalities, prematurity <35 weeks). We used agglomerative hierarchical clustering to 
group individuals with ASD relative to multiple sources of behavioral and clinical exam 
information. Association analyses were performed using the Family-Based Association 
Test (FBAT)114. We tested the null hypothesis of no association in the presence of 
linkage using the empirical variance-covariance estimator under an additive, multi-allelic 
genetic model113. We performed three FBAT analyses for the AGRE dataset according 
to the phenotypic subgrouping (Figure 3.2). 
Figure 3.2. Analysis Plan Schematic: AGRE Dataset. Three single-SNP 
association analyses and subsequent pathway analyses were performed on the 
discovery dataset based on different ASD phenotype definitions. All=no phenotypic 
subgrouping; 'Less Severe'=individuals in the less severe subgroup; 'More 
Severe'=individuals in the more severe subgroup. 
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For the first analysis, affection status was assigned to all individuals meeting criteria 
for an ASD diagnosis on both the ADI-R and the ADOS, regardless of phenotypic 
subgrouping. There were 48 males and 37 females in this dataset that were evaluated 
on both the ADI-R and ADOS and did not meet diagnostic criteria for an ASD on either 
instrument. These individuals were coded as unaffected. We also analyzed the data with 
the 85 unaffected individuals alternatively coded as unknown and compared FBAT 
results at each SNP. There were no differences in p-value for evaluated SNPs. For the 
second analysis, affection status was assigned only to individuals in a ‘less severe’ 
subgroup. Cases in this subgroup have scores indicating less severe measures for 
interrogated behavioral and clinical exam information. Cases assigned to the alternate 
subgroup were coded with unknown affection status. For the third analysis, affection 
status was assigned only to individuals in a ‘more severe’ subgroup. Cases in this 
subgroup have scores indicating more severe measures for interrogated behavioral and 
clinical exam information (Table 3.1). 
Deviation from the expected chi-square distribution was visualized in quantile-
quantile plots generated with a unique source code and the ggplot2 package in R210, 224. 
Population substructure does not cause type I error in family-based association tests, 
however, due to the diverse genetic ancestry of the evaluated dataset, genomic inflation 
factors (λ) were estimated for results from each FBAT analysis using the GenABEL 
package for R20. Manhattan plots were produced using a unique source code and the 
Table 3.1. Breakdown of Affection Status for Single-SNP Analyses: AGRE 
Dataset. Reported are the numbers of individuals evaluated for informative 
transmissions in Family-based Association Tests. 
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ggplot2 package in R210, 224. The estimation of odds ratios (ORs) and 95% confidence 
interval (CI) calculations for evaluated SNPs were performed using UNPHASED52. To 
determine the overall OR for genes of interest, an average was calculated for all SNPs 
located within each gene boundary. 
 
Pathway Analyses: AGRE dataset 
Three separate pathway analyses were performed with the Pathway Analysis by 
Randomization Incorporating Structure (PARIS) pathway analysis software package229 
using p-values generated in the corresponding single-SNP analysis (i.e. 'Analysis 1.1', 
'1.2', '1.3'). By assigning SNPs to genes based on chromosomal locations and looking 
for functionally-defined gene sets with an overrepresentation of significant SNPs, PARIS 
identifies biological pathways of interest. Since we expected that there would be many 
variants of minor effect working together, we set a less-stringent threshold (p<0.05) for 
SNPs entered into the subsequent pathway analyses to ensure this information was 
captured. We evaluated 209 pathways defined in the Kyoto Encyclopedia of Genes and 
Genomes (KEGG) database for pathway-based association101. SNPs were assigned to a 
pathway gene if it fell within +/−50 kb of the ENSEMBL genomic interval (build hg19). 
Hapmap CEPH samples (release 27) were used to account for patterns of linkage 
disequilibrium (LD). Bonferroni corrected significance for evaluated pathways was 
p≤0.0002. However, PARIS was currently only designed to generate pathway p-values 
as low as p<0.001. Also, many KEGG pathways contained overlapping genes and each 
significance test was not independent. Therefore, we chose the most stringent 
significance threshold available (p<0.001) for pathway-based results. 
Since the primary functional focus of pathways defined in the KEGG database is not 
neurodevelopment, in order to more thoroughly understand the relationship of identified 
pathways to ASD we felt it was necessary to further subject significantly associated 
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KEGG-defined pathways to permutation-based investigations and identify ‘core’ genes 
driving overall pathway associations. We defined ‘core’ genes as genes whose p-value 
in the context of the biological pathway was p<0.001, and upon removal from pathway 
analysis reduced the significance of the overall pathway above the significance 
threshold. To determine the overall OR for 'core' genes, an average was calculated for 
all SNPs located within the gene boundary, while taking into account the direction of the 
effect 
 
Single-SNP Association and Pathway Analyses: AGP Dataset 
We performed three FBAT validation analyses in the AGP dataset similar to that 
described above for the AGRE dataset (Figure 3.3). The breakdown of affection status 
for subgroup-specific single-SNP analyses is reported in Table 3.2.  
Nominally significant SNPs (p<0.05) from each of the single-SNP association 
analyses were subsequently evaluated in respective pathway analyses, via PARIS, as 
described above for the AGRE dataset (Figure 3.3). 
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Figure 3.3. Analysis Plan Schematic: AGP Dataset. Three single-SNP association 
analyses and subsequent pathway analyses were performed on the validation 
dataset based on different ASD phenotype definitions. All=no phenotypic 
subgrouping; 'Less Severe'=individuals in the less severe subgroup; 'More 
Severe'=individuals in the more severe subgroup. 
Table 3.2. Breakdown of Affection Status for Single-SNP Analyses: AGP 
Dataset. Reported are the numbers of individuals evaluated for informative 
transmissions in Family-based Association Tests using the AGP dataset. 
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Results 
 
Single-SNP Association Analyses: AGRE Dataset 
A total of 507,675 SNPs were analyzed for association in the discovery analyses. These 
SNPs were evaluated for association with all individuals meeting diagnostic criteria for 
an ASD on both the ADI-R and ADOS (Single-SNP Analysis 1.1), only affected 
individuals assigned to the ‘less severe’ phenotypic subgroup (Single-SNP Analysis 1.2), 
and only affected individuals assigned to the ‘more severe’ ASD subgroup (Single-SNP 
Analysis 1.3) (Figure 3.2). Genomic inflation factors for these analyses were 1.028, 
1.020, and 1.011, respectively (Figure 3.4). This indicates that population structure had 
no appreciable impact on our results49. No SNPs met a Bonferroni corrected significance 
threshold of p≤9.85x10
-8
 for any of the three association analyses (Figure 3.5).  
From Single-SNP Analysis 1.1, there were 26,970 SNPs (p<0.05) further evaluated 
in Pathway Analysis 1.1. From Single-SNP Analysis 1.2, 26,712 SNPs were evaluated in 
Pathway Analysis 1.2 and from Single-SNP Analysis 1.3, 26,335 SNPs were evaluated 
in the Pathway Analysis 1.3. Only 655 SNPs were associated (p<0.05) in all three 
analyses. 5,703 SNPs were associated (p<0.05) in Single-SNP Analyses 1.1 and 2, but 
not Analysis 1.3. 11,291 SNPs were associated (p<0.05) in Single-SNP Analyses 1.1 
and 1.3, but not Analysis 1.2. 743 SNPs were associated (p<0.05) in Single-SNP 
Analyses 1.2 and 1.3, but not Analysis 1.1. 9,321 SNPs were only associated (p<0.05) 
when all affected individuals were considered together, regardless of phenotypic 
subgroup assignment. 19,611 SNPs were uniquely associated (p<0.05) with individuals 
assigned to the ‘less severe’ phenotypic subgroup. 13,646 SNPs were uniquely 
associated (p<0.05) with individuals assigned to the ‘more severe’ phenotypic subgroup. 
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Figure 3.4. AGRE QQ Plots. Quantile-quantile plots of p-values from FBAT 
evaluating single-SNP associations with: a. all affected individuals b. 'less severe' 
subgroup c. 'more severe' subgroup. λ=genomic inflation factor; s.e.=standard error  
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Figure 3.5. AGRE Genome-wide Single-SNP Association Results. Manhattan 
plots of p-values from FBAT evaluating SNP associations with: a. all affected 
individuals b. 'less severe' subgroup c. 'more severe' subgroup. Red line=Bonferroni 
corrected significance threshold (p≤9.85x10
-8
). 
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Pathway-Based Analyses: AGRE Dataset 
We evaluated 209 pathways defined in the KEGG database for pathway-based 
association. We performed three separate pathway-based analyses using p-values 
generated via the three separate single-SNP analyses described above. We chose a 
threshold for significance at p<0.001 for pathway-based results. Seven KEGG pathways 
were associated (p<0.001) with in the full AGRE dataset. Three of these pathways 
remained associated when evaluating only the ‘more severe’ subgroup, while no 
pathways remained significant when evaluating only the ‘less severe’ subgroup (Table 
3.3). Five KEGG pathways were exclusively associated (p<0.001) with cases in the ‘less 
severe’ subgroup (Table 3.3). Five different KEGG pathways were associated (p<0.001) 
with the ‘more severe’ subgroup. Two of these pathways were not associated in either of 
the other two pathway analyses (Table 3.3). 
  Associated KEGG pathways were further subjected to permutation-based 
investigations to identify ‘core’ genes driving pathway associations. We defined ‘core’ 
genes as any gene whose p-value, in the context of the biological pathway, was p<0.001 
and upon removal from analysis, the overall pathway p-value increased such that the 
Table 3.3. Pathway-based Association Results: AGRE Dataset. Listed are 
biological pathways defined in the KEGG database that were associated (p<0.001) 
with at least one affection group. All=no phenotypic subgrouping; “LS”=individuals in 
the LS subgroup; “MS”=individuals in the MS subgroup. 
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previously implicated mechanism no longer met the significance threshold (Table 3.4). 
We identified 35 core genes within KEGG pathways associated (p<0.001) with all 
affected individuals, eight of these core genes function in ≥2 of these associated 
pathways. There are 39 genes total that associate (p<0.001) with all affected individuals, 
not all of these genes represent core genes driving pathway associations. Eleven of 
these genes did not meet our significance threshold for association in analyses where 
individuals were further defined by phenotypic subgroup (Table 3.5). We identified ten 
core genes within KEGG pathways associated (p<0.001) with the ‘less severe’ 
subgroup, five of these core genes function in ≥2 of these pathways. There are 18 total 
candidate genes associated (p<0.001) with the ‘less severe’ subgroup, eight of these 
genes did not meet our significance threshold when evaluating all affected individuals 
together, or the ‘more severe’ phenotypic subgroup (Table 3.5). We identified 24 core 
genes within KEGG pathways associated (p<0.001) with the ‘more severe’ subgroup, 10 
of these genes function in ≥2 of these pathways. There are 34 total candidate genes 
associated (p<0.001) with the ‘more severe’ subgroup, 12 of these did not meet our 
significance threshold in any other analysis (Table 3.5). 
Table 3.4. Pathway-based Associations Following Removal of 'Core' Genes. 
Reported are p-values for biological pathways of interest following removal of SNPs 
assigned to suspected core genes. P-values in bold italics indicate these pathways met 
the significance threshold (p<0.001) in the full pathway-analysis for this affection group. 
All=no phenotypic subgrouping; 'LS'=individuals in the LS subgroup; 'MS'=individuals in 
the MS subgroup. NCG=no core genes included in analyses. 
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  Single-SNP Association Analyses: AGP Dataset 
A total of 779,343 SNPs were analyzed for association in the validation analyses. 
These SNPs were evaluated for association with all AGP dataset individuals meeting 
diagnostic criteria for an ASD on both the ADI-R and ADOS (Single-SNP Analysis 2.1), 
only affected individuals assigned to the ‘less severe’ phenotypic subgroup (Single-SNP 
Analysis 2.2), and only affected individuals assigned to the ‘more severe’ ASD subgroup 
(Single-SNP Analysis 2.3) (Figure 3.3). Genomic inflation factors for these analyses 
were 1.028, 1.017, and 1.017, respectively (Figure 3.6). Nine SNPs met a Bonferroni 
corrected significance threshold of p≤6.42x10
-8 
in Single-SNP Analysis 2.1 (Figure 3.7). 
Associations for these markers have not previously been reported as the sex 
chromosomes were not included in these analyses134. However, the current version of 
FBAT allows for evaluation of markers on the sex chromosomes 
(http://www.biostat.harvard.edu/fbat/fbat.htm). Further information on SNPs surpassing a 
Bonferroni corrected significance threshold is provided in Table 3.6 and Figure 3.8.  
From Single-SNP Analysis 2.1, there were 41,331 SNPs (p<0.05) that were 
evaluated in Pathway Analysis 2.1. From Single-SNP Analysis 2.2, 40,953 SNPs were 
evaluated in Pathway Analysis 2.2. From Single-SNP Analysis 2.3, 40,375 SNPs were 
evaluated in Pathway Analysis 2.3. Only 1,140 SNPs were associated (p<0.05) in all 
three analyses. 10,531 SNPs were associated (p<0.05) in Single-SNP Analyses 2.1 and 
2.2, but not Analysis 2.3. 15,730 SNPs were associated (p<0.05) in Single-SNP 
Analyses 2.1 and 2.3, but not Analysis 2.2.  1,016 SNPs were associated (p<0.05) in 
Single-SNP Analyses 2.2 and 2.3, but not Analysis 2.1. 13,930 SNPs were associated 
(p<0.05) only when all affected individuals were considered together, regardless of 
phenotypic subgroup assignment. 28,266 SNPs were uniquely associated (p<0.05) with 
individuals assigned to the ‘less severe’ phenotypic subgroup. 22,489 SNPs were 
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uniquely associated (p<0.05) with individuals assigned to the ‘more severe’ phenotypic 
subgroup. 
 
Figure 3.6. AGP QQ Plots. Quantile-quantile plots of p-values from FBAT evaluating single-
SNP associations with: a. all affected individuals b. 'less severe' subgroup c. 'more severe' 
subgroup. λ=genomic inflation factor; s.e.=standard error. 
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Figure 3.7. AGP Genome-wide Single-SNP Association Results. Manhattan plots of p-
values from FBAT evaluating SNP associations with: a. all affected individuals b. 'less 
severe' subgroup c. 'more severe' subgoupr. Red line=Bonferroni corrected significance 
threshold (p≤6.42x10
-8
). 
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Pathway-Based Analyses: AGP Dataset 
To determine which AGRE associated KEGG pathways validated in the AGP 
dataset, we chose a threshold for pathway significance at p<0.05. A total of seven 
pathways validated in the AGP dataset at this significance threshold. The pathway 
defined in KEGG as ‘Bacterial invasion of epithelial cells’ validated not only across 
datasets, but was associated with the ‘more severe’ subgroups from both datasets 
(Table 3.7; Figure 3.9). The other six pathways that validate in the AGP dataset are 
associated independent of phenotypic subgroup assignment. For example, the pathway 
defined as ‘Allograft rejection’ is associated (p<0.001) with the ‘less severe’ AGRE 
subgroup and the ‘more severe’ AGP subgroup (Table 3.7). There are another 13 KEGG 
pathways that are trending towards significance (p<0.05) in at least one analysis for both 
datasets (Table 3.8). We further investigated validated pathways to identify genes 
driving pathway associations and compared these results with core genes identified with 
the AGRE dataset (Table 3.9). Four core genes identified in the ‘less severe’ AGRE 
subgroup analysis validated (p<0.001) in the ‘less severe’ AGP subgroup analysis, and 
five core genes identified in the ‘more severe’ AGRE subgroup analysis validated 
(p<0.001) in the ‘more severe’ AGP subgroup analysis (Table 3.9). In some cases, the 
same specific gene did not validate but genes within the same gene family were 
identified as driving pathway associations in both datasets. For example, the ARPC3 
and ARPC5 genes are significantly associated (p<0.001) with the ‘more severe’ AGRE 
subgroup while the ARPC1A gene is significantly associated (p<0.001) with the ‘more 
severe’ AGP subgroup (Figure 3.9). 
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Discussion 
 
Our results show that different genetic factors are uniquely associated with ASD 
subgroups defined using multiple sources of behavioral and clinical exam information. 
This suggests that meaningful phenotypic subgroup definitions can help clarify the 
underlying genetic etiology of ASD. Further, the pathway-based approach seemed to be 
a more biologically relevant way to evaluate the risk effects of common, inherited 
variation, as opposed to single-variant analysis. The vast majority of the SNPs evaluated 
did not meet a multiple-testing adjusted significance threshold when analyzed 
individually. However, by evaluating the combined effects from many SNPs, we were 
able to identify groups of genes with similar function contributing to risk for ASD and 
effectively account for underlying genetic heterogeneity across two independent ASD 
datasets. By using the combined approach of phenotypic subgrouping and pathway-
based genetic analysis, we were able to implicate functional pathways of interest and 
refine the genetic bottlenecks related to specific ASD traits. 
By subgrouping individuals based on similar expression of ASD-related phenotypes, 
we drastically reduced the number of cases evaluated in subgroup-specific analyses 
(AGRE=35%-65% reduction; AGP=40%-60% reduction). Despite these substantial 
reductions in sample size, subgroup-specific odds ratio (OR) calculations for core genes 
that were also associated when analyzing all cases together indicate no reduction in 
observed genetic effects. In fact, the effects on risk only seem to increase in subgroup-
specific analyses. This suggested our method of phenotypic subgrouping potentially 
reduced statistical noise and increased the ability to detect genetic effects. 
Performing phenotypic subgroup-specific genetic analyses also allowed us to more 
easily refine potential phenotype-genotype relationships. For example, we observed that 
pathways and 'core' genes related to adaptive immunity were almost exclusively 
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associated with the ‘less severe’ AGRE subgroup. Two 'core' genes in all of the 
pathways associated with the ‘less severe’ AGRE subgroup were located in the major 
histocompatibility complex (HLA-B, HLA-G). Increasing evidence supports substantial 
neural-immune crosstalk starting in the fetal brain and continuing throughout life38, 145. 
Many members of the major histocompatibility complex are thought to play important 
roles in brain development and function, reviewed in Needleman & McAllister, 2012153. 
Multiple studies have also identified extensive changes in the immune systems of 
individuals with ASD, reviewed in Careaga, 201037. Interestingly, two pathways 
significantly associated with the ‘less severe’ AGRE subgroup are ‘autoimmune thyroid 
disease’ and ‘type-I diabetes mellitus’. A few epidemiological studies have reported 
associations between both of these diseases and ASD19, 149, 150. Specifically, 
autoimmune thyroid disease is more frequent in children diagnosed with a regressive 
form of ASD, compared to children diagnosed with an early-onset form149. It is assumed 
that cases with regressive ASD exhibit less delayed early development100. We saw that 
the ‘abnormality of development evident ≤ 36 months’ domain score from the ADI-R 
stood out as having a strong influence on assignment of individuals to our ASD 
subgroups. Higher scores on this measure indicate very severe abnormality of 
development observed early in life. All individuals assigned to the ‘less severe’ AGRE 
subgroup had low severity scores on this measure; it is possible that some of these 
individuals exhibited a regressive form of ASD. Cases in the AGP subgroups were older, 
on average, at the time of ADI-R than were cases in the AGRE subgroups 
(tMoreSevere=5.01, p<0.00001; tLessSevere=2.10, p=0.017). A larger portion of individuals in 
the ‘more severe’ AGP subgroup have less severe scores on the 'abnormality of 
development evident ≤ 36 months’ measure compared to individuals in the ‘more severe’ 
AGRE subgroup (zMannWhitney=10.73, p<0.00001). If cases with regressive ASD do exhibit 
less delayed early development, but have more severe presentation later in life, then 
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ADI-R evaluations performed in older individuals should indicate lower severity scores 
on the ‘abnormality of development evident ≤ 36 months’ domain score, but greater 
severity scores on other ADI-R domains. Our results connecting immune system 
function uniquely with phenotypically-defined ASD subgroups support the idea that 
immune dysfunction is not linked with all forms of ASD, but is confined to specific 
subphenotypes of ASD37. 
Our results indicate applying a pathway-based approach to analysis of genome-wide 
ASD data helps account for underlying genetic heterogeneity. This was apparent when 
comparing genes in the same biological pathway that were associated with subgroups 
from the two independent datasets. For example, results from the AGRE analyses show 
the ‘taste transduction’ pathway is very significant (p<0.001) when case status is defined 
using solely diagnostic criteria (Pathway Analysis 1), but not when more extensive 
phenotype definition is used to classify ASD subgroups (pLessSevere=0.018; 
pMoreSevere=0.124). Upon further investigation of core genes driving the association with 
this pathway, we see unique genomic features associate (p<0.001) with the ‘less severe’ 
subgroup (ADCY4, PRKACA, TAS2R16, ADCY8) and others the ‘more severe’ (KCNB1, 
GNAS, TAS2R13, TAS2R14, TAS2R43, TAS2R31, TAS2R46, TAS2R19, TAS2R20, 
TAS2R50, TAS2R42). While the same exact genes have not to our knowledge been 
previously implicated in ASD, the chromosomal locations coding these genes have been 
found linked to male-only subgrouped phenotypes205 and affected sib-pairs97. Also, a 
SNP near the TAS2R1 gene on chr5p15 was identified in a GWAS of exclusively 
multiplex families221. Neither the specific taste receptor gene nor assigned SNPs were 
significant (pTAS2R1=1.000; pSNPs≥0.0595) in our studies. One set of taste-related genes 
appear to be working in the 'less severe' subgroup, and another subset in the 'more 
severe' subgroup. It is conceivable that multiple different genes functioning in one, or a 
few pathways, could lead to many different phenotypic consequences, culminating in the 
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autistic spectrum. There is substantial evidence supporting this concept in ASD, 
reviewed in Geshwind, 200869. 
Another example of how genetic heterogeneity was accounted for is the association 
of the pathway described as ‘Bacterial invasion of epithelial cells’. This pathway is very 
significant (p≤0.002) when case status is defined using solely diagnostic criteria for both 
datasets. When affected individuals from both datasets are further defined into ‘less 
severe’ subgroups, this association signal is no longer significant (pAGRE‘LessSevere’=0.538, 
pAGP‘LessSevere’=0.689). However, when affected individuals from the two datasets are 
further defined into ‘more severe’ subgroups the pathway association remains significant 
(pAGRE‘MoreSevere’<0.001, pAGP‘MoreSevere’=0.021). Upon further investigation of 'core' genes in 
this pathway, we observed that different genes were associated with the 'more severe' 
AGRE subgroup when compared to the 'more severe' AGP subgroup. While the same 
specific gene did not validate, genes within the same family and different genes with 
similar predicted function related to single transduction and cell motility were identified 
as driving the pathway's association with both datasets. For example, the ARPC3 and 
ARPC5 genes were significantly associated with the ‘more severe’ AGRE subgroup 
while the ARPC1A gene was significantly associated with the ‘more severe’ AGP 
subgroup. In a typical single-SNP approach to analysis of GWAS data, or candidate 
gene analyses, the validated association of this mechanism with the AGP dataset would 
have gone unnoticed. Known functions of core genes driving the associations for this 
pathway in the ‘more severe’ subgroups relate to single transduction and cell motility, 
processes crucial to proper neurodevelopment. Interestingly, some of these core genes 
have been previously linked to ASD, and in some cases with specific endophenotypes. 
For example, the genomic region encoding ARPC5L (9q33-q34) was found linked in 
multiplex families when using ‘age at first word’ from the ADI-R as a quantitative trait179. 
This item is included in calculating the ‘abnormality of development evident ≤ 36 months’ 
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domain score and a majority of cases with very severe scores for this measure are 
assigned to the ‘more severe’ ASD subgroups. 
Other interesting pathways identified initially when analyzing all diagnostically-
defined cases, upon subgrouping, appear to be uniquely associated with the ‘more 
severe’ AGRE subgroup (p’MoreSevere’<0.001; p’LessSevere’≥0.538). The ‘Neurotrophin 
signaling pathway’ validated, however exclusively in the ‘less severe’ AGP subgroup 
(p’LessSevere’=0.003; pAll=0.168; p’MoreSevere’=0.106). Many of the core genes driving the 
pathway association in the ‘more severe’ AGRE subgroup have previously been 
implicated in nonverbal ASD subgroups. Linkage at interval chr1p13–q12 to nonverbal 
cases was originally observed in multiplex AGRE families41. We identified three core 
genes in the ‘Neurotrophin signaling pathway’ located within this interval (JUN, NRAS, 
and NGF).  The nerve growth factor (NGF) gene is also a core gene in the ‘Apoptosis’ 
pathway which was uniquely-associated (p<0.001) with the ‘more severe’ AGRE 
subgroup. Fine-mapping in the previously linked chr1p13-q12 interval detected 
associations for three haplotype blocks, intronic to the NGF gene, in more AGRE 
families131. Further studies identified an association to the NGF gene region in an AGP 
dataset, having simplex and multiplex families. However, this association was to a 
different haplotype block than the associated AGRE haplotypes and LD calculations 
indicated these signals were independent. We did not validate direct association to the 
NGF gene in the AGP dataset evaluated in our analyses (pAll=0.134; p’LessSevere’=0.612; 
p’MoreSevere’=0.145). Interestingly, there are proportionally more nonverbal individuals in 
the AGRE subgroups compared to the AGP subgroups (z’LessSevere’=5.09, p<0.00001; 
z’MoreSevere’=15.88, p<0.00001). These results may further support a relationship between 
variations in the NGF gene and nonverbal ASD subgroups. 
While we were able to validate a portion of pathways and core genes identified in the 
AGRE dataset in the AGP dataset, numerous pathways either do not validate, or 
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validate in a different subgroup classification. Despite our success developing and 
applying novel multivariate statistical methods to identify genetically meaningful ASD 
subgroups in both datasets, there are still substantial phenotypic differences between 
the AGRE and AGP datasets and similarly-defined subgroups from the two datasets. 
These differences are potentially why we observe distinct genetic signals when 
comparing results for similarly-defined subgroups from the two datasets. For instance, 
recent research has suggested that both the phenotypic expression and underlying 
genetic architecture of ASD in multiplex families is distinct from that in simplex 
families216. Many of the previously reported candidate genes we found associated with 
the ‘more severe’ AGRE subgroup, that do not validate in the ‘more severe’ AGP 
subgroup, were initially identified in exclusively multiplex families, or in analysis of 
subgroups from the AGRE dataset. The majority of families in the evaluated AGRE 
dataset are multiplex (91.2%) compared to a minority of families in the evaluated AGP 
dataset (31%). Kruskal-Wallis tests show family structure is significantly different 
(p<0.0001) when comparing both the ‘less severe’ subgroups and ‘more severe’ 
subgroups defined in both datasets. The proportion of multiplex families evaluated in 
AGRE subgroups was also significantly higher than in AGP subgroups (z’LessSevere’=15.28, 
p<0.00001; z’MoreSevere’=15.35, p<0.00001). There is also previous evidence indicating 
sex-specific genetic effects underlying ASD129. Similar to our observations regarding 
dataset-specific family structure, gender is very different between the AGRE ‘less 
severe’ subgroup and the AGP ‘less severe’ subgroup (p=0.0063) as well as the AGRE 
‘more severe’ subgroup and the AGP ‘more severe’ subgroup (p=0.0021). The 
proportion of females evaluated in AGRE subgroups was significantly higher than in 
AGP subgroups (z’LessSevere’=2.73, p=0.003; z’MoreSevere’=2.15, p=0.016). It is also notable 
that the AGRE and AGP samples were genotyped on two different microarray SNP 
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platforms. 3.4% of the pathway-analyzed SNPs identified in the AGRE dataset were not 
genotyped in the AGP dataset. 
We observed strong associations for nine sex chromosome SNPs in the AGP single-
SNP analyses. Five SNPs located on the pseudoautosomal region of the X/Y 
chromosomes, and four SNPs located on the X chromosome pass the threshold for 
Bonferroni-adjusted significance (p≤6.42x10
-8
) (Figure 3.8; Table 3.6). It is difficult to 
assess the validity of these very significant SNPs. This is mainly due to the statistical 
limitations involved in evaluating associations for sex-specific genetic markers. These 
markers were also not assayed on the platforms used to genotype the discovery AGRE 
dataset. We performed pathway-based analyses with and without these SNPs included 
and saw no appreciable effects on the significance of associations. This is not 
unexpected, two of these SNPs are not within +/-50kb of any predicted gene boundaries, 
one SNP is assigned to a pseudogene (SSX6), and one SNP is assigned to a long 
intergenic non-protein coding RNA (XR_110926.1). For the remaining SNPs, there is 
previous evidence supporting the involvement of the assigned genes in underlying 
mechanisms of ASD. SNP rs2896799 (ORAll_AGP≈6.19; 95% CI=3.77-10.16) is located 
inside gene boundaries for both KAL1 and VCX3B. KAL1 is predicted to be involved in 
neurite outgrowth, axon guidance and branching, and cell adhesion55. All developmental 
mechanisms thought to be involved in ASD96, 152, 202. The involvement of VCX3B in ASD 
etiology has also been implicated via inherited deletions of this genomic region43. SNP 
rs909439 (ORAll_AGP≈12.72; 95% CI=5.54-29.20) is located in VAMP7, a gene also 
known to be involved in neurite outgrowth9, 10. Two SNPs, rs34013457 (ORAll_AGP≈5.24; 
95% CI=3.21-8.56) and rs34537684 (ORAll_AGP≈7.53; 95% CI=4.47-12.69), are located in 
PCDH11. This gene is a member of the protocadherins family. Other genes in the 
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protocadherins family have been previously implicated statistically, and via their 
functions in synaptic cell-adhesion pathways27. 
The pathway-based approach seems to be a more biologically relevant way to 
evaluate the effects of common, single genetic variants, especially in a group of 
disorders known to be as complex and heterogeneous as ASD.  We show our method of 
phenotypic subgrouping is genetically relevant and that using a pathway-based 
approach to evaluate genetic effects on ASD risk is an effective way to account for 
genetic heterogeneity, implicating more refined biological mechanisms. By further linking 
functional pathways of interest and refining the genetic bottlenecks effecting proper 
pathway function related to specific ASD traits, there may be potential to discover more 
effective methods of symptom treatment. 
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CHAPTER IV 
 
EVALUATING SMALL MOLECULE EFFECTS ON EXPRESSION OF AN AUTISM 
CANDIDATE GENE: ACETYLSEROTONIN O-METHYLTRANSFERASE 
 
Introduction 
 
Uncovering pathways associated with subgroups of ASD has elucidated potential 
sets of genes involved in expression of certain ASD traits. However, to progress toward 
understanding how these significant findings contribute to disorder process, further 
functional characterization of these associations is necessary. Most genes identified 
through pathway analysis have some known biological function but the relationship of 
these genes to ASD is likely unknown. While some progress has been made, there is 
still much to learn about pathophysiology and pharmacology in ASD146, 217.  
Many children with ASD are currently treated with medical interventions, yet little 
evidence exists to support the benefit of these treatments146. Evidence also supports 
significant exhibition of adverse side effects of many medications thereby limiting their 
use to certain ASD patients78, 110, 146, 185. The emerging field of pharmacogenetics is 
concerned with studying the effects of genetic factors on drug response. Previous 
pharmacogenetic studies suggest that the altered efficacy and varied side effects seen 
with many drugs used to treat neurological disorders are related to individual genetic 
variation109, 124, 174. Furthermore, evidence from a study evaluating antidepressant 
efficacy suggests that single nucleotide polymorphisms (SNPs) located in promoter 
regions directly affect patient response to drug treatment120. Single base-pair changes in 
the genetic code could allow or disrupt binding of small molecule compounds, causing a 
drug response in a patient with this variant different from that observed in individuals 
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without these changes. Screening for gene expression effects of small molecule 
compounds has been used previously toward compound profiling and lead discovery144, 
211. We applied this concept to functional characterization of known ASD-related SNPs to 
determine if they cause the gene to respond differently to small molecule compounds 
when compared to the genotype not associated with ASD. 
Acetylserotonin O-methyltransferase (ASMT), also known as Hydroxyindole-O-
methyltransferase, is the initial candidate gene we chose to test for genotype-specific 
altered gene expression effects in vitro when cell lines are exposed to small molecule 
compounds. ASMT encodes the enzyme that catalyzes the final reaction in melatonin 
synthesis. Numerous studies have reported abnormal levels of melatonin in individuals 
with ASD175 and sleep disorders are common in patients with the disorders with 
prevalence estimates ranging from 39-80%73, 111, 137, 190. Melatonin is involved in 
regulating the sleep-wake cycle in humans and is synthesized in the pineal gland5, 33, 140. 
Synthesis of melatonin begins with the active uptake of the amino acid tryptophan into 
the gland. Tryptophan is then hydroxylated and decarboxylated to serotonin, another 
molecule with ample evidence for involvement in ASD83. Serotonin is then N-acetylated 
by the rate-limiting enzyme in this pathway, arylalkylamine, and subsequently converted 
to melatonin by the ASMT enzyme5. 
Melatonin supplementation is an emerging approach to treating sleep defects in 
ASD, however some patients are non-responders175. Other patients undergoing 
melatonin treatment report relief from comorbid symptoms like irritable bowel 
syndrome220, anxiety and seizures189, while some exhibit more severe symptoms23, 78, 185. 
These seemingly contradictory findings suggest that underlying genetic architecture may 
affect exhibition of adverse side effects resulting from melatonin treatment. These 
findings are not exclusive to treatment with melatonin. Interestingly, for many other 
compounds used to treat comorbid symptoms of ASD, individuals report sleep problems 
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as adverse side effects146. One possible explanation is that these small molecule 
compounds are somehow perturbing the melatonin synthesis pathway, potentially by 
affecting expression of ASMT. 
The involvement of ASMT in ASD etiology has been studied extensively99, 148, 175, 219. 
There are three isoforms of the ASMT gene resulting from alternative splicing of exons 6 
and 751. There are also two distinct putative promoters reported, promoter A and 
promoter B171.  Previous tissue-specific expression studies indicate promoter A is 
expressed almost exclusively in the retina, while promoter B drives ASMT expression in 
high amounts in the pineal gland. There are two SNPs located in promoter B of ASMT 
that have been statistically associated with increased ASD risk, rs4446909 and 
rs5989681. Additionally, homozygous presence of the risk alleles for both SNPs was 
correlated with a significant decrease in ASMT expression and ASMT enzymatic activity 
in patients148. The ASMT promoter polymorphisms conferring risk for ASD are located in 
transcription factor binding sites for nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) and specificity protein 1 (Sp1)99. As such, the reported SNPs 
are thought to alter gene expression by disrupting transcription factor binding. An ASD-
risk haplotype has also been reported that includes the promoter B SNPs and a third 
SNP, rs6644635, located in the 5'-untranslated region (UTR) of the only know functional 
isoform of ASMT30, 148, 219. 
We hypothesized that the ASMT gene promoter B could be a target for small 
molecule compounds and wanted to determine the effects of current ASD treatments on 
genotype-specific ASMT expression. The goal is to determine if effects of individual 
genetic variation, in relation to ASMT expression, could help explain the observed 
inefficacy and adverse side effects of certain drugs used to treat ASD comorbid 
symptoms. The ultimate goal for all pharmacogenetic studies is to provide evidence 
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useful toward optimizing more effective medical treatments for each person’s unique 
genetic architecture. 
 
Methods 
 
Choice of Cell Type 
We used previously generated lymphoblast cell lines derived from individuals 
ascertained by our lab and collaborators. We chose to utilize lymphoblast cell lines 
(LCLs) to allow evaluation of small molecule effects in the endogenous melatonin 
system. Promoter B is reported to be actively expressed in LCL and these cells are the 
same lines used by Melke et al, 2008 to identify the published ASMT genotype-specific 
gene expression, indicating gene expression of the candidate gene should be detectable 
in these cells.  Further, melatonin biosynthesis has been reported in human 
mononuclear lymphocytes59. It is also important to note, LCLs have a relatively low 
reported somatic mutation rate at low passages (0.3%)186. 
 
Sequence Confirmation 
We screened DNA previously extracted from the blood of 22 individuals, in 15 ASD 
families, previously genotyped at the rs4446909 marker, for which cell lines were 
available. A region of ASMT, including the promoter B element, 5-UTR, and exon 1B, 
was amplified for each DNA sample via polymerase chain reactions (PCR) using the 
following primers: forward 5'-AAAAGGGGTCTCACTATGTTGC-3'; reverse 5'-
TGGAACGTGAGTGTGATG AAC-3'. Amplified products were purified from reactions 
with the QIAquick® PCR Purification Kit and Sanger sequenced at GenHunter® 
Corporation. Presence of the genotypes of interest at each SNP in the haplotype of 
interest was verified by analyzing raw sequence chromatograms. The linkage 
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disequilibrium (LD) map for SNPs of interest in this region was calculated using pairwise 
D' with Haploview.  
 
Cell Culture, DNA and RNA Isolation 
We chose two cell lines from affected individuals homozygous for the associated risk 
haplotype (rs4446909GG, rs5989681GG, rs6644635CC), and one cell line from an affected 
individual homozygous for the promoter B risk alleles and heterozygous at the third SNP 
in the haplotype (rs4446909GG, rs5989681GG, rs6644635CT). Two cell lines were also 
chosen from affected individuals heterozygous at all SNPs (rs4446909AG, rs5989681CG, 
rs6644635CT), and one cell line from an affected individual heterozygous for the 
promoter B risk alleles and homozygous at the third SNP in the haplotype (rs4446909AG, 
rs5989681CG, rs6644635CC). Finally, we chose three cell lines from individuals, two 
affected and one father, homozygous for the unassociated promoter B genotypes 
(rs4446909AA, rs5989681CC, rs6644635CC). Due to the lower frequency of these 
genotypes in our case population, it was necessary to choose one parental cell line. It 
was previously reported that individuals with homozygous non-risk genotypes at the 
promoter B SNPs had higher ASMT transcription regardless of case status. It was also 
shown that in parents of children diagnosed with ASD, ASMT transcription correlated 
with melatonin levels148. 
Cells were grown at 37°C in RPMI-1640 medium, plus L-glutamine (Life 
Technologies, Inc., Grand Island, NY, USA).  Growth media was supplemented with 
10% heat-inactivated, undialyzed fetal bovine serum (FBS), and 1% 
penicillin/streptomycin (10,000ug/ml) antibiotic. DNA was extracted using the DNeasy® 
Tissue Kit from Qiagen®. DNA extracted from cell lines was sequenced, as described 
above, to verify the correct sequence of interest in each line. Total RNA was isolated 
using the phenol/chloroform method. 
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Characterization of Basal ASMT Transcript Levels 
Over the course of 4 weeks, at one week intervals, RNA was extracted from each 
cell line. Oligo(dT)-primed cDNA was constructed from 5µg total RNA, using the 
Superscript II kit (Invitrogen, Grand Island, NY, USA), according to the manufacturer 
instructions, with RNase inhibitor. These cDNAs were standardized to the same 
concentration (100ng) and used directly in quantitative real-time PCR (qPCR). Multiplex 
qPCRs were performed, in triplicate, using the TaqMan® Fast Advanced Master Mix, on 
the Applied Biosystems® 7900HT Fast Real-Time PCR System. ASMT mRNA was 
quantified using a commercially available FAM-labeled TaqMan® assay spanning the 
boundary between exon 1B and exon 2 (Hs00946625_m1). Relative quantification of 
ASMT expression was determined using the comparative cycle threshold (2−ΔΔCt) 
method. Amplification efficiencies were determined using linear regression analysis 
performed on log fluorescence data (i.e. the inverse log of the slope in the log linear 
phase)66. ASMT expression was normalized to Ct values for a VIC-labeled TaqMan® 
assay spanning exons 1 and 2 of the polymerase (RNA) II (DNA directed) polypeptide A 
(POLR2A) gene (Hs00172187_m1). Statistical significance of qPCR results was 
determined using a Student’s two-tailed t-test, with unequal variance. 
 
Effects of FBS Serotonin Exposure on ASMT Expression 
We controlled for serotonin present in the FBS used for cell culture by adapting the 
cells into completely serum-free media and serum-starving them for at least 24 hours 
prior to performing small molecule treatments. We used AIM V® Medium, Liquid with 
Human Serum Albumin. To determine the effect of serum starvation on expression of 
ASMT, aliquots of cells from each line were spun down and resuspended in either the 
serum-supplemented ‘growth’ media or the serum-free ‘starvation’ media, to mimic the 
experimental environment of small molecule treatments. Resuspended cells were 
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allowed to grow for 24hrs and total RNA was isolated. Oligo(dT)-primed cDNA was 
constructed and RT-qPCRs were performed as described above. 
 
Small Molecule Treatments 
We focused small molecule experiments on five compounds currently used to treat 
symptoms in ASD, where reported side effects include sleep disturbances. These 
compounds were: Risperidone, Escitalopram, Fluoxetine, Serotonin and Melatonin. Prior 
to cell treatments, we ensured receptors for chosen compounds were expressed in 
human lymphocytes125, 139, 169, 191. Cell lines were spun down and resuspended in serum-
free media as described above. After at least 24 hours of serum-deprivation, when cells 
were in the mid-logarithmic phase of growth, six wells were plated for each cell line, at 
2.5 ml total volume per well. Small molecule treatments were performed with cells 
suspended in serum-free media. Experiments were standardized to have similar counts 
of cells/mL in each treatment well (i.e. cell counts were diluted to equal the well with the 
lowest cell count/mL and were ~500,000). Compounds were dissolved in DMSO+H2O 
and added to cells at concentrations comparable to clinical dosage, when available. For 
FDA approved drugs, treatment concentrations were determined based on reported 
peak plasma concentrations in humans11, 167, 226. Melatonin has yet to be approved by the 
FDA, however, pharmacokinetics of melatonin have been reported in older adults74 and 
a phase I trial has been performed to evaluate melatonin treatment for sleep problems in 
autistic individuals137. We used the reported effective dosages in autistic children at the 
corresponding reported peak plasma concentration from the study performed on older 
adults. For serotonin treatments, we used mean whole-blood 5-HT concentrations 
reported for children with ASD, which were shown to be higher when compared to 
healthy control children80. Negative controls were treated with vehicle-only (DMSO+H2O) 
(Table 4.1). Six hours after addition of compounds, 1mL of cells from each treatment 
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were aliquoted, spun down at 1,000g for 5 minutes, and frozen at -80°C. The remaining 
1.5mL were spun down at 1,000g for 5 minutes, and frozen at -80°C, 12 hours after 
addition of compounds. This treatment protocol was performed in three experimental 
replicates over the course of one week to minimize potential biases that may arise due 
to different batches of growth media and serum-free media, and cell passages. Total 
RNA was isolated from cells from the first small molecule treatment experiments. 
Randomly-primed cDNA was constructed, without RNase inhibitor, using the High-
Capacity cDNA Reverse Transcription Kits from Applied Biosystems. RT-qPCRs were 
performed, in triplicate, as described above. 
 
Compound Drug (g) 
DMSO 
(ml) 
Compound 
Initial 
Concentration 
(ng/ml) 
Final Concentration 
(ng/ml) 
Final 
Volume 
Added 
to Cells 
(ul) 
Risperidone 0.0005 0.1 50000 15.90 0.80 
Melatonin 0.0001 1.0 150000 18.80 0.31 
Fluoxetine 0.0006 0.1 62500 171.00 6.84 
Escitalopram 0.0015 0.1 170000 278.80 4.10 
Serotonin 0.0017 0.1 1000 4.00 10.00 
Negative 
Control: 
DMSO+H2O 
NA 1.0 NA 1ml DMSO:100ml H2O 10.00 
 
 
 
 
Table 4.1. Compound Dilutions for Cell Line Treatments. Reported are the final 
concentrations and amounts of small molecule compounds added to cell lines for 
experimental treatments. All compounds were initially dissolved in the recommended 
amount of DMSO. Initial compound dilutions were then diluted further with 100mL 
H2O to allow pipettable volumes for experiments. 
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Results 
 
Sequence Confirmation 
Sequencing of the ASMT promoter B element and 5'-UTR for the 21 affected 
individuals (15 males and 7 females), we evaluated indicates low levels of LD across the 
three markers previously reported to be inherited as a risk haplotype for ASD (Figure 
4.1). 
 
 
Characterization of Basal ASMT Transcript Levels & Effects of FBS Serotonin Exposure 
on ASMT Expression 
Results from qPCR for these experiments show Cts vary widely across triplicates and 
reactions have low amplification efficiencies (efficiencies < 80%). Evaluation of the raw 
amplification plots show that expression of the endogenous control gene we chose, 
POLR2A, is extremely variable across triplicates, and in many cases has lower Ct-values 
than the gene of interest. 
 
Figure 4.1. Haplotype block structure 
of the promoter B and 5'-UTR SNPs in 
ASMT. Reported are the relative position 
of each SNP, and the pairwise LD (r2) 
between all SNPs. 
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Small Molecule Treatments 
Amplification efficiencies for qPCR are low for a majority of these reactions. 
Efficiencies for negative controls treated with vehicle-only range from 66%-128% for the 
ASMT assay, and 73%-83% for the POLR2A assay. We potentially see significantly 
(p≤0.03) decreased ASMT expression for individuals homozygous for risk alleles at the 
promoter B SNPs, compared to individuals homozygous for the alternative alleles at 
these SNPs. We also observe significant reductions in ASMT expression for individuals 
heterozygous at the two promoter B SNPs, compared to individuals homozygous for the 
alternative alleles at these SNPs (Table 4.2; Figure 4.2). 
Table 4.2. Fold Change Differences By Genotypes. Reported are results from 
Student’s t-tests, with unequal variance. Genotypes are indicated in order of 
chromosomal location: rs4446909/rs5989681/rs6644635. Asterisks denote calibrator 
sample, statistics for this sample are reported for the mean calculated across 
triplicates. All other statistics represent those calculated for the fold change difference 
observed. Std. Err.=standard error, 95% CI=95% confidence interval. 
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We observed one sample having a potentially significant increase (p=0.02) in ASMT 
expression after exposure to Serotonin for 12 hours. This did not replicate across the 
other two samples with the same combination of genotypes at the three SNPs of interest 
(AA/CC/CC). We did not observe any other significant changes in ASMT expression 
following exposure of cells with the non-risk genotypes to any of the other evaluated 
compounds (Figure 4.3). Results from qPCR for treatment experiments on samples 
heterozygous or homozygous for risk genotypes vary widely across triplicates and are 
inconclusive. 
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Sample Genotypes For Each SNP 
Figure 4.2. Genotype-Specific ASMT Gene Expression. Quantification of ASMT 
transcripts relative to genotypes of interest for each SNP. Genotypes are indicated in 
order of chromosomal location: rs4446909/rs5989681/rs6644635. Statistical 
significance determined via Student’s t test with unequal variance. *p ≤ 0.03. 
* 
* * * * * 
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Discussion 
 
We observe higher recombination rates between SNPs in the predicted risk 
haplotype for our small subset of samples, compared to currently reported estimates in 
larger European and Han Chinese descent ASD cohorts148, 219. The previously reported 
structure for the ASMT promoter B SNPs and 5'-UTR SNP suggests strong linkage 
disequilibrium (LD) across all three markers. D' estimates between the two promoter B 
SNPs, rs4446909 and rs5989681, suggest the two SNPs are inherited more often as a 
Figure 4.3. Effects of Small Molecule Treatments on ASMT Gene Expression: 
Non-Risk Alleles. Quantification of ASMT transcripts following exposure to evaluated 
small molecule compounds for the non-risk haplotypes. Genotypes are indicated in 
order of chromosomal location: rs4446909/rs5989681/rs6644635. Statistical 
significance determined via Student’s t test with unequal variance. *p = 0.03. 
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haplotype (D’=0.92-0.94). This is also true for reported D' estimates between rs4446909 
and rs6644635 (D'=0.84), and rs5989681 and rs6644635 (D'=0.98)148, 219. We are 
reporting pairwise measures of the squared correlation coefficient (r2), since D' 
calculations in our evaluated samples are not informative. Due to the equation used to 
calculate the D' statistic, missing genotype combinations always result in D'=1. There are 
missing genotype combinations between markers rs4446909 and rs598968, and 
markers rs598968 and rs6644635. Our estimates of r2 suggest these three SNPs are not 
inherited as a haplotype block in these ASD families. 
Unfortunately, we were unable to ensure that the level of ASMT expression in our 
cell lines was stable over a four-week time course. However, previous evidence 
suggests ASMT mRNA expression and enzymatic activity in the pineal gland does not 
fluctuate based on diurnal rhythms4. We were also unable to determine the effect of 
serum-deprivation on expression of ASMT. Interestingly, the observation that POLR2A 
had lower expression than ASMT for most samples was only in reactions using the 
Oligo(dT)-primed cDNA prepared with an RNase Inhibitor. There is previous evidence 
suggesting decreases in POLR2A mRNA levels are attributable to RNase H-mediated 
cleavage of the mRNA206. It is possible that by treating cDNA samples with RNase H we 
affected expression of our endogenous control, rendering the qPCR results unreliable. 
We evaluated seven different potential control genes prior to performing these qPCR 
experiments. The goal was to obtain a normalizer gene with Ct-values similar to those 
observed for ASMT. An alternative gene we anticipate using in future experiments is 
GAPDH. 
By evaluating qPCR results from vehicle-only treated controls, our data are 
consistent with previous findings indicating homozygous presence of the risk alleles at 
the promoter B SNPs, rs4446909 and rs5989681, results in decreased ASMT gene 
expression148. Previous reports also suggest the observed decrease in expression was 
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only attributable to homozygosity for risk alleles at these two SNPs. There are no 
reported effects on ASMT gene expression attributable to heterozygosity at the promoter 
B SNPs or to any genotype at the 5'-UTR SNP, rs6644635. We do observe decreased 
ASMT expression when individuals are heterozygous, compared to homozygous non-
risk genotypes at these markers. This is very preliminary and to accurately determine the 
effects of heterozygosity at these markers on ASMT expression would require further 
experiments aimed at modeling the effect of genotypes at each SNP alone and 
conducted on cDNA extracted from entirely untreated cells. 
Initial results suggest there are no large changes in ASMT gene expression upon 
exposure to small molecule compounds at either the 6 or 12 hour time point for the non-
risk haplotype. Again, reaction efficiencies are low and estimates of relative ASMT 
quantities are highly variable across triplicates. This is especially true for samples where 
ASMT transcript production is already reduced in negative controls. It is possible the low 
level of expression for our candidate gene in LCL is too low to be accurately detected via 
qPCR. It is also possible that exposure to the small molecule compounds alter 
expression of our chosen endogenous control gene. The low reaction efficiencies could 
also be attributable to pipetting error, poor PCR primer design, a result of multiplexing 
the reaction, or cDNA concentrations that are too low, or high, to be detected 
accurately108. It is difficult to determine the effects of small molecule compound exposure 
on ASMT expression using these reported results. Future experiments, directed at 
optimizing the qPCR, will be necessary to formulate conclusions from our small molecule 
treatments. 
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CHAPTER V 
 
CONCLUSION 
 
Summary 
Autism Spectrum Disorder exhibits multiple levels of complexity related to clinical 
manifestation and etiology. There are many mechanisms implicated in ASD, including, 
but not limited to, biological epistasis, genetic heterogeneity, gene-environment 
interactions, and epigenetic effects. The research conducted in this dissertation was 
motivated by the idea that the difficulty in identifying genetic variation with strong effects 
on risk for ASD is due to the wide variability in clinical manifestation, being explained in 
large part by underlying genetic heterogeneity. 
We hypothesized that phenotypic heterogeneity could be one phenomenon 
complicating identification of genetic factors. By performing unsupervised clustering, 
based on a myriad of carefully chosen phenotypic information, derived from more than 
one source, we were able to effectively evaluate a broad array of information and enable 
a more complete phenotype definition for subsets of individuals with ASD. The 
overlapping interpretation of our results from two different multivariate analyses, PCA 
and clustering, demonstrate the utility of this approach. That we were able to show 
defined subgroups of phenotypic expression appearing to be genetically meaningful in 
the AGRE dataset and replicate these findings in an independent AGP dataset lends 
further support to the validity of the resulting cluster groupings and the idea that the 
phenotype clusters recapitulate underlying genetic mechanisms in Autism Spectrum 
Disorders. 
To further support this idea, we see that unique biological mechanisms are 
implicated when comparing genes associated with either the ‘more severe’ or ‘less 
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severe’ ASD subgroups. Our results suggest that meaningful phenotypic subgroup 
definitions can help clarify the underlying genetic etiology of Autism Spectrum Disorders. 
The pathway-based approach seems to be a more biologically relevant way to evaluate 
the effects of common, single genetic variants, especially in a group of disorders known 
to be as complex and genetically heterogeneous as ASD.  We show that using a 
pathway-based approach to evaluate genetic effects on ASD risk is an effective way to 
account for genetic heterogeneity, implicating more refined biological mechanisms. By 
further linking functional pathways of interest and refining the genetic bottlenecks 
effecting proper pathway function related to specific ASD traits, there may be potential to 
discover more effective methods of symptom treatment. 
Results from our functional pharmacogenetic analyses evaluating genotype-specific 
small molecule effects on expression of ASMT are largely inconclusive and will need to 
be evaluated further in future studies. However, our data are consistent with previous 
results indicating homozygous presence of risk alleles at the promoter B SNPs 
significantly reduces ASMT expression. We also have potentially implicated previously 
unreported gene expression effects related to heterozygosity. We did not observe any 
conclusive effects of compound treatment on expression in the non-risk haplotype. This 
may indicate that altered efficacy and presentation of adverse sleep-related events are 
not attributable to deregulation of ASMT. 
 
Future Directions 
We chose to conduct completely separate analyses in the AGRE and AGP datasets. 
The initial goal was to determine the replicability of the phenotypic subgrouping. As 
such, it was necessary to run independent multivariate statistical analyses in these 
datasets. However, the utility of this approach may not have been the most powerful 
option in our subsequent genetic analyses. There are many potential reasons that a 
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portion of the sub-group specific genetic results, identified in the AGRE dataset, did not 
validate, or validate in a different subgroup, in the AGP dataset. A number of these 
potential reasons are discussed in more detail in Chapter III. To truly replicate genetic 
analyses in the AGP dataset, it will be necessary to perform a confirmatory factor 
analysis by applying the same cluster analysis and principal component loadings 
identified in the AGRE dataset, to the AGP dataset. In other words, to fit phenotype 
characteristics of individuals in the AGP dataset into the defined AGRE clusters. 
It is interesting to speculate at potential genotype-phenotype relationships resulting 
from pathway analyses of the main cluster groupings. However, there is still substantial 
phenotypic heterogeneity in these main subgroups within the same dataset. It would be 
beneficial to further evaluate genetic contributions to ASD-related phenotypes in the 
smaller subclusters, as opposed to main clusters. The defined subclusters within each 
main cluster seem to represent ASD subgroups with more homogeneous phenotypic 
expression than the main clusters, and could be very informative for these types of 
evaluations. For example, an interesting analysis would be to evaluate genetic 
contributions in the 'youngest' subclusters. These subclusters grouped separately from 
the other subclusters within the ‘more severe’ main clusters for both datasets. 
Since the functional focus of the KEGG database is definition of primarily metabolic 
pathways, it would be interesting to evaluate other pathway databases more potentially 
relevant to functional mechanisms implicated in ASD. We have evaluated the Gene 
Ontology database with PARIS and have numerous interesting results from these 
analyses that could be evaluated in future studies. Preliminary examination of the Gene 
Ontology results show that some of the core genes identified in the KEGG database 
analyses overlap with genes in the Gene Ontology database, but many strongly 
associated genes are unique. 
97 
 
To obtain more conclusive and reliable results from our small molecule experiments, 
it will be necessary to further troubleshoot qPCR and try to obtain tighter cycle 
thresholds for triplicates. Obtaining an endogenous control gene that is not affected by 
exposure to small molecule compounds is an important next step. In the future, we 
would like to run qPCR normalizing to a primer-limited assay for GAPDH, to determine if 
compounds do have genotype-specific functional effects that do not relate directly to 
ASMT expression. It would be interesting to evaluate potential expression effects of 
these small molecules on other genes in the melatonin pathway. It may be that the 
expression of other genes in the melatonin pathway is dependent on endogenous ASMT 
expression, which is altered due to the genotype-specific effects of SNPs in the ASMT 
promoter B and 5-UTR. It would also be relevant to perform unbiased transcriptome 
profiling using RNA extracted from our treated cells to evaluate potential expression 
effects on many genes that function in other pathways, in addition to the melatonin 
pathway. 
 
The importance of determining the relationship of genotype to phenotype in all 
aspects of genetic analysis of complex disease cannot be overstated. Most of the ASD 
risk genes identified, especially via pathway-based analysis, have some known 
biological function, but the relationship of these genes to ASD is largely unknown. The 
currently known list of ASD risk genes and other genetic abnormalities need to be 
extensively studied to truly understand the functional consequences of each variation. 
While progress has been made, there is still much to learn about pathophysiology and 
pharmacology in ASD. 
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